header logo image


Page 16«..10..15161718..30..»

Archive for the ‘Molecular Genetics’ Category

Unity and EU-wide Efforts Focus of Online Rare Disease Meeting – Hemophilia News Today

Tuesday, May 19th, 2020

Eurordis, a Paris-based coalition of national rare disease associations across Europe, hosted its first all-virtual conference, bringing some 1,500 delegates from 57 countries together online during the COVID-19 pandemic.

The 10th European Conference on Rare Diseases & Orphan Products (ECRD2020) which was set for May 1415 in Stockholm, instead took place via Zoom. Eurordis and its co-organizer, Orphanet, used the occasion to appeal to the European Union in Brussels to urgently approve standardized policies to advance the health and well-being of all Europeans.

Yann Le Cam, CEO of Eurordis, said that as is the case with COVID-19, there is an obvious value to grouping efforts at the EU level in order to tackle rare diseases. But he lashed out at the increasing nationalism shown by various leaders responding to the pandemic.

We must quash this egocentric rhetoric emerging in some countries. It fragments Europe into diverging national-level decisions, Le Cam, of France, said in his welcoming remarks. A lack of EU coordination is both detrimental to the health of people living with a rare disease and has an unnecessary negative impact on the economy.

He urged the EU to take the following concrete steps:

This epidemic has shown that if you fail to prepare, you prepare for failure and we must prepare together across borders, said Terkel Andersen, president of the Eurordis board.

Eurordis is a nonprofit alliance of 900 rare-disease patient organizations from 72 countries that work jointly to improve the lives of Europeans with rare diseases. Orphanet provides high-quality information and data on rare diseases. With its 40-nation network, Orphanet helps to orient patients and doctors to relevant expert resources in Europe and beyond.

The EU considers a disease rare if its incidence is lower than 1 in 2,000 people. About 30 million of the 446 million citizens who live in its 27 member states have a rare disease.

Yet because of the low prevalence of each disease, medical expertise is uncertain, care offerings inadequate, and research limited, said Orphanets director, Ana Rath. She noted that 72% of rare diseases are genetic and that 70% of those genetic conditions begin in childhood.

Now more than ever, the EU has a vital role to play in improving the health of its citizens. ECRD2020 focuses on how to build policies and services over the next decade that will improve the journey of living with a rare disease for patients and families, Rath said.

Attendance at this years virtual conference was up 81% compared to the 850 people who attended ECRD2018 in Vienna. It followed six broad themes, ranging from the future of diagnosis to the digital health revolution.The online conference program ran 54 pages, with specific breakout sessions covering topics from newborn screening for genetic diseases to how best to bring real life into therapeutic development.

Several top EU officials addressed participants via Zoom, including Stella Kyriakides, the European commissioner for health and food safety. She said ECRD2020 builds on the work of the ongoingRare 2030 Foresight Study, which will conclude in 2021 with a comprehensive set of key recommendations to EU leaders on how to improve rare disease policy.

In the coming years, we will be guided by the Rare 2030 Foresight Study, Kyriakides said. We need now to take lessons from COVID-19. We know that patients will be the driving force of our rare disease policy.

Europe currently accounts for more than one-third of the 4.7 million confirmed COVID-19 infections worldwide, with cases stretching from Madrid to Moscow. Infection rates, however, varies widely among EU member states.

Another major theme of ECRD2020 was how to ensure non-discrimination on the basis of health and disability. Officials addressing that theme included David Lega, a Swedish member of the European Parliament; Jana Popova of the Bulgarian Association for Neuromuscular Diseases; and Helena Dalli, European commissioner for equality.

All people should be able to participate fully and equally in society and in the economy, Dalli said. It is not only their right. Their participation represents a huge contribution to the whole society.

The ECRD2020 conference was co-chaired by Maria Montefusco, president of Rare Diseases Sweden; Milan Macek, a professor of medical and molecular genetics at Motol University Hospital in Prague; and Violeta Stoyanova-Beninska, chair of the Committee of Orphan Medical Products at the Amsterdam-based European Medicines Agency.

Florida native Larry Luxner, a veteran journalist and photographer, has reported from more than 100 countries in Latin America, Africa, Eastern Europe, the Middle East and Asia for the Miami Herald, the Washington Diplomat, the Journal of Commerce and other news outlets. He lived for many years in San Juan, Puerto Rico, and the Washington, D.C., area. Among other ventures, he launched a monthly newsletter, South America Report, and later published CubaNews for 12 years before relocating to Israel in January 2017 and joining BioNews first as a copy editor and now as a staff writer. Larry is fluent in Spanish, Portuguese and Hebrew, and enjoys taking long walks around Tel Aviv in his spare time.

Total Posts: 46

Jos holds a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimers disease.

Visit link:
Unity and EU-wide Efforts Focus of Online Rare Disease Meeting - Hemophilia News Today

Read More...

Dr. Bankole Johnson Partners with the Exclusive Haute MD Network – PR Web

Tuesday, May 19th, 2020

Professor Johnsons primary area of research expertise is on ion channels, neuropsychopharmacology, molecular genetics, mathematics, neuroimaging, and medications for treating addictions. He holds several US and International patents in pharmacogenetics.

MIAMI (PRWEB) May 19, 2020

The Haute MD Network, well known for its exclusivity, and luxurious lifestyle, is privileged to present Dr. Bankole Johnson as a leading addiction expert representing the Miami/ Ft. Lauderdale Market and the newest addition to the Haute Living partnership.

Haute MD offers a prominent collective of leading doctors nationwide. The invitation-only exclusive network maintains elite as ever, with only two doctors in every market. This partnership allows Haute MD to connect its affluent readers with industry-leading doctors.

Visit Dr. Bankole's Haute MD Profile: https://hauteliving.com/hautebeauty/mdmember/dr-bankole-johnson/

About Dr. Johnson:

Professor Bankole A. Johnson, D.Sc., M.D., MBChB, MPhil, FRCPsych, DFAPA, Dip-ABAM, Dip-ABDA, FACFEI

Professor Johnson (2013 2019) served as The Dr. Irving J. Taylor Professor and Chair in the Department of Psychiatry, and Professor of Anatomy & Neurobiology, Medicine, Neurology, and Pharmacology at the University of Maryland School of Medicine. He directs all brain sciences across multiple departments at the School under the aegis of the Brain Science Research Consortium Unit, which grew in NIH funding from $21M-$35M from 2013-2018. Professor Johnson serves as the Director of the Clinical Neurobehavioral Center in Columbia.

Previously (2004 2013), Professor Johnson was the Alumni Professor and Chair of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia and was a Professor in the departments of Neuroscience and Medicine.

Professor Johnson graduated in Medicine from Glasgow University in 1982, and trained in Psychiatry at the Royal London, Maudsley, and Bethlem Royal Hospitals. Additional to his medical degree, he obtained a Master of Philosophy degree for his neurobiological research at the University of London and conducted studies in neuropsychopharmacology for his doctoral thesis (degree from Glasgow University) on the Medical Research Council unit at Oxford University. In 2004, Professor Johnson earned his Doctor of Science degree in Medicine from Glasgow Universitythe highest degree that can be granted in science by a British university.

Professor Johnsons primary area of research expertise is on ion channels, neuropsychopharmacology, molecular genetics, mathematics, neuroimaging, and medications for treating addictions. He holds several US and International patents in pharmacogenetics. Professor Johnson is a licensed physician and board-certified psychiatrist. He is the Principal Investigator on National Institutes of Health (NIH)-funded research studies from basic science to molecular and clinical studies, and has been funded continuously for over two decades. Professor Johnson has been awarded or been affiliated with over $40M in NIH funding. Professor Johnsons clinical expertise is in the fields of addiction, forensics, and disability assessment. Honors include service on numerous NIH review and other committees including special panels. Briefly, Professor Johnson was the 2001 recipient of the Dan Anderson Research Award for his distinguished contribution as a researcher who has advanced the scientific knowledge of addiction recovery. He received the Distinguished Senior Scholar of Distinction Award in 2002 from the National Medical Association. Professor Johnson also was an inductee of the Texas Hall of Fame in 2003 for contributions to science, mathematics, and technology, and in 2006 he received the American Psychiatric Associations (APAs) Distinguished Psychiatrist Lecturer Award. In 2007, he was named as a Fellow in the Royal College of Psychiatrists, and in 2008 he was elected to the status of Distinguished Fellow of the APA. In 2009, he received the APAs Solomon Carter Fuller Award, honoring an individual who has pioneered in an area that has benefited significantly the quality of life for Black people. In 2010, he was named as a Fellow in the American College of Neuropsychopharmacology. He received the NIHs Jack Mendelson Award in 2013 for landmark discoveries in addiction science. In 2016, he received a Governors citation for service on the Maryland Heroin and Opioid Emergency Task Force. In 2019, he will receive the R. Brinkley Smithers award from the American Association of Addiction Medicine.

Professor Johnson has served as Editor-in-Chief and on the Editorial Boards of prestigious medical journals, and reviewed for more than 30 journals in pharmacology, neuroscience, and the addictions. He has authored 161 peer-reviewed publications, received over 17,000 citations, has an i10 index of 155, and an h-index of 58.

Professor Johnson is the founder and was the Chairman of Adial Pharmaceuticals, Inc., a publicly listed (on the NASDAQ) pharmaceutical Company till august 2019 (now he is its Chief Medical Officer), which developed as a start-up at the University of Virginia.

Share article on social media or email:

Read the original:
Dr. Bankole Johnson Partners with the Exclusive Haute MD Network - PR Web

Read More...

Could sewers be the key to tracking coronavirus? – Environment Journal

Tuesday, May 19th, 2020

Engineers believe wastewater could bey key to tracking the spread of coronavirus.

An international team of researchers that includes engineers from the University of Sheffield are developing new techniques that could be used for a number of potential uses including to identify a second wave of the pandemic.

They say wastewater monitoring offers a quick way to identify the level of infection in a community without the need for testing individuals. The techniques could then help create a more accurate map of how the virus is spreading.

Brought together by the Water Research Foundation, the group is currently developing best-practices and standardised procedures for collecting and storing water samples as well as using molecular genetics tools to identify levels of COVID-19 in wastewater samples.

They are also developing strategies to communicate the implications of environmental surveillance results with the public health community, elected officials, wastewater workers, and the public.

Professor Vanessa Speight, who is also a member of the Sheffield Water Centre at the University said: There is great potential for wastewater to provide valuable information about the occurrence of COVID-19 across communities. But given that this is a very new field of investigation, we have identified a number of areas where future research efforts should be concentrated to maximise the value of this data.

Photo Credit the University of Sheffield

Read more:
Could sewers be the key to tracking coronavirus? - Environment Journal

Read More...

Second wave of coronavirus could be spotted in sewage – sciencefocus.com

Tuesday, May 19th, 2020

Scientists are developing ways of using sewage to locate new infection hotspots and track a second wave of COVID-19.

An international group of waste water experts are researching new techniques that could identify the level of infection in a community without the need for testing individuals.

New standardised procedures could identify the virus in waste water and provide a picture of how coronavirus is spreading, the researchers said.

The group, who were brought together by the Water Research Foundation and include engineers from the University of Sheffield, are developing a range of best practices concerning the use of sewage.

These include collecting and storing waste water samples and using molecular genetics tools to identify levels of COVID-19 in sewage samples.

The scientists are also developing recommended approaches for using levels of coronavirus in waste water samples to inform trends and estimates of the spread of the virus in communities and developing strategies to communicate the implications of the results with the public.

Read the latest coronavirus news:

Professor Vanessa Speight, from the University of Sheffields Department of Civil and Structural Engineering, is researching techniques to reliably interpret the data collected from sewage samples.

Her results could help create a more accurate map of how the virus is spreading and show the emergence of a second wave of the pandemic.

She said: There is great potential for waste water to provide valuable information about the occurrence of COVID-19 across communities.

On Monday, Prime Minister Boris Johnson said a new alert system to monitor the threat posed by coronavirus could eventually identify local flare-ups if COVID-19 is detected in the waste water from a local area.

The PMs official spokesman said: Some studies have been carried out overseas on this and I think it is something we are looking at as a possible way of seeing if you could track the rate of infections locally.

The Downing Street spokesman said officials are investigating whether sewage samples would allow them to track if the virus is more prevalent in some parts of the country than in others.

A family in Bradford watch Britains Prime Minister Boris Johnson give a televised message to the nation to announce a new alert system on Sunday George Wood/Getty Images

Experts said some countries are testing waste water to see if there is an infection in the community.

And, while there is no evidence of the live virus being found in sewage or that the virus has been spread through sewerage systems, one study from the Netherlands found viral genetic material in waste water samples several weeks before the first case was detected.

A spokesman from the Department for Environment, Food and Rural Affairs (Defra) said: We are actively engaging with the research community and Government scientific advisers to investigate whether monitoring waste water could be used as a way of tracking the prevalence of the virus.

Last month, scientists from Newcastle University said they were collaborating with Spanish academics to monitor sewage in their local networks in both countries to estimate the prevalence of COVID-19 in north-east England and across Spain.

Asked by: Andrew Cirel, via email

Strictly speaking, viruses cant die off as theyre just inanimate strips of genetic material plus other molecules. But the reason that they keep coming back is because theyre always infecting someone somewhere; its just that at certain times of the year, theyre less able to infect enough people to trigger a full-blown epidemic.

Many viruses flare up during the winter because people spend more time indoors in poorly-ventilated spaces, breathing in virus-laden air and touching contaminated surfaces. The shorter days also lead to lower levels of vitamin D, and this weakens our disease-fighting immune system. Experiments also suggest that the flu virus in particular remains infectious for longer in low temperatures.

But even when conditions arent ideal, viruses will find enough people to infect to ensure their survival, until they can come roaring back in an epidemic.

Read more:

Read the rest here:
Second wave of coronavirus could be spotted in sewage - sciencefocus.com

Read More...

Prominent Cancer Researcher to Join DRI and Renown Health – GlobeNewswire

Tuesday, May 19th, 2020

The Desert Research Institute (DRI) and Renown Health proudly announce the addition of Dr. Pier Paolo Pandolfi, MD, PhD, FRCP to the DRIs faculty of the Renown Institute of Health Innovation and as Director of the Institute of Cancer at Renown Health.

Reno, Nevada, May 18, 2020 (GLOBE NEWSWIRE) -- Reno, Nev. (May 18, 2020) Today, the Desert Research Institute (DRI) and Renown Health proudly announce the addition of Dr. Pier Paolo Pandolfi, MD, PhD, FRCP to the DRIs faculty of the Renown Institute of Health Innovation and as Director of the Institute of Cancer at Renown Health.

Dr. Pandolfi, a prominent cancer investigator and molecular geneticist, will build a translational cancer laboratory at DRIs campus in Reno, Nevada to expand the success of the Healthy Nevada Project (the largest, community-based population health study combining genetic, clinical, environmental and social data, and offering free genetic testing to every Nevadan) into translational medicine and create a world-class cancer research and clinical care program.

Dr. Pandolfi will divide his time between Reno and Italy, also leading a cancer research institute in his home country that will foster knowledge exchange and international cancer research collaborations between Italy and Nevada.

As a cancer researcher, my mission is to cure cancer. The Healthy Nevada Project and the combined resources of Renown Health and DRI give us access to an unprecedented amount of longitudinal data and the valuable genetic information we need to continue to improve our understanding of the molecular mechanisms of cancer and tailor approaches for treatments and cures that are unique to each individual said Dr. Pandolfi.

I am proud to take the unique resource of the Healthy Nevada Project, and use the information to accelerate our work to provide a population-level view of those factors that drive cancer, build better models and perhaps, timely new treatments. I am excited to build a strong collaborative bridge between the state of Nevada with our colleagues in Italy and across Europe, which will allow for the exchange of research fellows, physicians, scientists, and interns, added Pandolfi.

Dr. Pandolfi, a scientist whom the NIH deems outstanding, and who is leading significant contributions toward the understanding of cancer and genetics, is formerly the director of the cancer center at Beth Israel Deaconess Medical Center at Harvard Medical School in Boston and prior to that at Memorial Sloan Kettering Cancer Center in New York.

His extraordinary career in the molecular understanding of cancer has resulted in major medical breakthroughs in the treatment of solid tumors and leukemia. His foundational work in the study of critical cancer genes as models for tumor suppression has helped explain the causes of acute promyelocytic leukemia (APL) and led to the development of innovative and effective treatments and therapies for the disease.

Recognizing the need to expand the Healthy Nevada Project into a new era of translational medicine, we are very excited to welcome Dr. Pandolfi and his pioneering scientific bench-to-patient bedside approach, said Anthony Slonim, M.D., Dr.PH., FACHE, president and CEO of Renown Health and co-founder of the Renown Institute for Health Innovation and the Healthy Nevada Project. Dr. Pandolfis arrival in Nevada represents a significant milestone for all of us, especially those of us who are cancer survivors. Nearly 4 in 10 of us will be diagnosed with cancer, the second-leading cause of death in the US. Dr. Pandolfi understands how genomics provides new tools for the prevention and early detection of many cancers.

Through the Healthy Nevada Project, 50,000 Nevadans volunteered their genetic information. Dr. Pandolfi will use the insights gained during the first two phases of the Healthy Nevada Project to plan future research.

Dr. Pandolfi brings with him to Nevada, a prestigious National Institutes of Health (NIH), National Cancer Institute Outstanding Investigator award. This grant provides stable, long-term research funding to support the research activities of the Renown Institute of Health Innovation.

Dr. Pandolfi will also serve as Director of the Renown Institute for Cancer and further a goal to bring world-class, exceptional cancer care to Nevada. He will lead efforts to streamline, standardize, and personalize relationships at every point in the cancer care continuum screening, diagnosis, treatment, and the care provided for survivors as well as those at the end of life. In addition, Dr. Pandolfis strong connections with the research community facilitate matching Renown patients to the right clinical trials, another example of Renowns position at the leading edge of treatment while developing the cancer care of the future.

The study of human health and its connection to our environment has always had a place in DRIs mission and research activity, said Kumud Acharya, Ph.D., Interim President of DRI. We are proud to welcome Dr. Pandolfi to Nevada and we are thankful for this extraordinary opportunity to meaningfully expand our health sciences research capacity to serve Nevada, together with our partners at Renown Health.

A native of Rome, Dr. Pandolfi received his MD in 1989 and Ph.D. in 1995, both from the University of Perugia, Italy. He completed his post-graduate work at the Royal Postgraduate Medical School, University of London, before joining the faculty of Memorial Sloan-Kettering Cancer Center and the Weill Graduate School of Medical Sciences at Cornell University in New York in 1994.

He is the author of more than 450 peer-reviewed research papers and the recipient of more than 30 awards and honors, including the Leukemia and Lymphoma Society of America Stohlman Scholar Award; the Weizmann Institute of Science: Sergio Lombroso Prize for Cancer Research; the William and Linda Steere Foundation Award; and the prize for Scientific Excellence in Medicine from the American-Italian Cancer Foundation. He has also been awarded the Fondazione Cortese International Award; the Prostate Cancer Foundation Creativity Award; and the Guido Venosta Award for Cancer Research.

In 2006, Dr. Pandolfi was elected as a member of the American Society for Clinical Investigation and the American Association of Physicians and in 2007 became a member of the European Molecular Biology Organization. In 2015, Dr. Pandolfi was Knighted by the Republic of Italy, receiving the Officer of the Order of the Star of Italy by the President of the Italian Republic. More recently, Dr. Pandolfi has been elected Fellow of the American Association for the Advancement of Science (AAAS) in 2017 and Fellow of the Royal College of Physicians of London in 2018.

For more about the Renown Institute for Health Innovation at DRI please visit http://www.dri.edu/renown-ihi/.

The Renown Institute for Health Innovation is a collaboration between Renown Health a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe, and northeast California; and the Desert Research Institute a recognized world leader in investigating the effects of natural and human-induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the states access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies.

See original here:
Prominent Cancer Researcher to Join DRI and Renown Health - GlobeNewswire

Read More...

New combination treatment may overcome drug resistance in blood cancers – UBC Faculty of Medicine

Tuesday, May 19th, 2020

Scientists at UBC and BC Cancer have found a new combination treatment for blood cancers that may lead to more effective results, especially in patients at high risk of drug resistance and disease progression.

Dr. Shoukat Dedhar

The new finding, recently published in Cell Stem Cell, builds off a more than two decades-old discovery of an enzyme called integrin-linked kinase (ILK), first identified by Dr. Shoukat Dedhar, professor in UBC faculty of medicines department of biochemistry and molecular biology and distinguished scientist at BC Cancer.

Scientists have now made a significant advancement in understanding the role this enzyme plays in blood cancers.

Working alongside Dr. Dedhar, the studys senior author Dr. Xiaoyan Jiang, UBC professor in the department of medical genetics and distinguished scientist at BC Cancer, and Dr. Katharina Rothe, the studys first author and UBC postdoctoral research fellow at BC Cancer, found that ILK is highly abundant in chronic myeloid leukemia (CML), which accounts for approximately 15 to 20 per cent of all adult leukemia at diagnosis.

Dr. Katharina Rothe

They also found that when this enzyme is inhibitedin combination with current standard treatmentthe results are more effective. In fact, combining the standard treatment with the ILK enzyme inhibitor made the drug-resistant cancer stem cells more sensitive to the treatment, while not being toxic to healthy stem cells.

According to Dr. Jiang, the effect is due to the fact that ILK-inhibition specifically targets dormant cancer stem cells that standard treatment cant target on its own.

These dormant cancer stem cells are a big problem for drug resistance and relapse, says Dr. Jiang. Most drugs only treat bulk cancer cells that are dividing and growing. But these dormant cancer stem cells are not in cell division so they remain untreatable. This is dangerous because those cells are left alive in the body. A patient can be in remission for years and all of a sudden, without warning, the cancer stem cells begin dividing and this can cause relapse.

Dr. Xiaoyan Jiang

Dr. Jiang and Dr. Connie Eaves, UBC professor in medical genetics and distinguished scientist at BC Cancer, discovered this critical dormant CML stem population nearly 20 years ago.

Current treatments for CML are life-long, meaning that most patients need to continue treatment even when in remission because the cancer stem cells linger and contribute to drug resistance and relapse. With CML, there is a high relapse rate for patients who stop receiving treatment even for a few weeks. In some cases, the cancer returns in a form that is untreatable.

The next step will be phase one clinical trials following some modifications to the ILK enzyme inhibitor to make it more stable for consumption.

Abnormal activity of ILK is associated with poor prognosis of cancer patients and this combination strategy may also apply to other forms of cancer where the ILK enzyme is highly increased.

A version of this story originally appeared on the BC Cancer website.

View original post here:
New combination treatment may overcome drug resistance in blood cancers - UBC Faculty of Medicine

Read More...

DOJ escalates Chinese ‘Thousand Talents’ crackdown with arrest of Cleveland Clinic researcher – Washington Examiner

Tuesday, May 19th, 2020

The Justice Department escalated its crackdown on Chinese influence within U.S. research institutions with the arrest of a Chinese American researcher at the Cleveland Clinic.

Dr. Qing Wang, a professor of molecular genetics at the Cleveland Clinic and Case Western University, was arrested Wednesday on charges of lying to investigators and wire fraud related to more than $3.6 million in funding that he and his research group at the Cleveland Clinic received from the National Institutes of Health under false pretenses. At the same time that he was receiving millions of dollars in U.S. government grants, court documents reveal he concealed how he was also the Dean of the College of Life Sciences and Technology at the Huazhong University of Science and Technology in Wuhan, China. He was also receiving grants from the National Natural Science Foundation of China and hid his participation in Chinas Thousand Talents Program, a Chinese Communist Party effort to recruit academics to gain access to foreign technology and intellectual property.

The Senate Permanent Subcommittee on Investigations, led by Sen. Rob Portman, released a 109-page bipartisan report in November, concluding that foreign countries seek to exploit Americas openness to advance their own national interests and that the most aggressive of them has been China. It found China used its Thousand Talents Program over the past two decades to exploit access to U.S. research labs and academic institutions. The FBI has deemed the Chinese effort to be a form of nontraditional espionage.

Wang, who was born in China but became a naturalized U.S. citizen in 2005, accepted a research position with the Cleveland Clinic in 1997 with a focus on genetics and cardiovascular disease. He was selected by China for its Thousand Talents Program in 2008. He made his initial court appearance on Thursday.

FBI agent John Matthews authored the 26-page criminal complaint against Wang, unsealed Thursday, which said Wangs false and fraudulent pretenses, representations, and promises led the NIH to approve and fund more than $3.6 million in grants via interstate wire transfer to him at the Cleveland Clinic. NIHs own rules say that overlap, whether scientific, budgetary, or commitment of an individual's effort greater than 100 percent, is not permitted.

The investigator said China increased its funding $3 million at HUST after he joined the Thousand Talents Program and that China paid for his trips there and provided him with a three-bedroom apartment on the Chinese campus. Wang admitted working to recruit people at Harvard Medical School, the University of California, and the University of Texas. He offered recruits between $200,000 and $300,000 in financial compensation on behalf of HUST.

Wang denied that he received any financial compensation from China for his participation in the Thousand Talents Program, which the FBI agent said was untrue.

Matthews said, The investigation determined that on at least four occasions, Dr. Wang had the opportunity and obligation to disclose his Chinese grants, his position as Dean at HUST, and the scientific, budgetary, and commitment of effort overlap between his NIH and CSNF grants, but knowingly and willfully failed to do so, in 2014, 2015, 2016, and 2017.

The Justice Departments China Initiative, launched in 2018, aims to combat both Chinese malign influence (ranging from cyberespionage to technology theft) and its Thousand Talents Program, which is aimed at stealing research. The department charged Chinese telecommunications giant Huawei in a global racketeering scheme earlier this year.

Portman said Thursday that he was pleased that our committee investigation and resulting report last year has spurred additional action by federal law enforcement to hold China accountable. The Ohio senator noted that for too long, China has exploited the lack of transparency in our education system to steal our taxpayer-funded research and innovation, and the federal government has done little or nothing to stop it.

Portman added: I will be introducing bipartisan legislation soon to safeguard American innovation, hold countries like China accountable for their actions, and ensure our world-class research enterprise is protected here in America. Chinas ongoing theft of Americas research and innovation must stop.

The arrest of Wang comes days after the Justice Department announced the arrest of Simon Saw-Teong Ang, an Arkansas professor who received millions of dollars of grant research money from the U.S. government, including $500,000 from NASA, on charges related to wire fraud. Angs research received $5 million in U.S. government contracts even as he allegedly failed to disclose his extensive financial connections to China and participated in Chinas Thousand Talents Program.

Dr. Xiao-Jiang Li, a former Emory University professor and Chinese Thousand Talents Program participant, pleaded guilty on Friday to filing false tax returns after he worked overseas at Chinese universities and did not report any of his foreign income on his federal tax returns.

In January, the Justice Department announced that Charles Lieber, the chairman of Harvards chemistry department, was charged with one count of making a materially false, fictitious, and fraudulent statement about his connections to Chinas Thousand Talents Program.

Link:
DOJ escalates Chinese 'Thousand Talents' crackdown with arrest of Cleveland Clinic researcher - Washington Examiner

Read More...

BostonGene Announces Acceptance of Abstracts to the Annual Meeting of the American Society of Clinical Oncology 2020 – BioSpace

Tuesday, May 19th, 2020

Abstracts Underscore the Results of Collaborations with Multiple Leading Cancer Centers in the United States

WALTHAM, Mass.--(BUSINESS WIRE)-- BostonGene Corporation, a biomedical software company focused on defining optimal, precision medicine-based therapies for cancer patients, today announced that, as a result of its strategic collaborations, seven abstracts have been accepted to the American Society of Clinical Oncology (ASCO) Annual Meeting. All abstracts to be published in the Journal of Clinical Oncology supplement for the ASCO Annual Meeting Proceedings.

We are honored to have multiple abstracts accepted by ASCO 2020. The studies demonstrate the clinical utility of BostonGenes advanced precision medicine capabilities and our commitment to transform the lives of cancer patients, said Andrew Feinberg, President & CEO at BostonGene.

Details of abstract presentations are as follows:

Abstract Number: 8055*

Title: Multi-omics analysis of mantle cell lymphoma reveals an immune-cold tumor microenvironment associated with ibrutinib resistance

Session: Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia

Presenter: Krystle Nomie, PhD, BostonGene

Poster: 388

Tumor-immune molecular programs were characterized from over 200 mantle cell lymphoma samples and correlated with response to ibrutinib.

Research conducted with The University of Texas MD Anderson Cancer Center

Abstract Number: 6561*

Title: Immune functional portraits of head and neck cancer using next generation sequencing

Session: Head and Neck Cancer

Presenter: Susan Raju Paul, MBBS, Vaccine and Immunotherapy Center, Massachusetts General Hospital

Poster: 222

BostonGenes comprehensive, integrated analysis of WES and RNAseq was used to characterize the cellular composition and functional state of over 1,400 head and neck tumors and their tumor microenvironment.

Research conducted with Massachusetts General Hospital

Abstract Number: 8054*

Title: Identification of Predicted Neoantigen Vaccine Candidates in Follicular Lymphoma Patients

Session Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia

Presenter: Cody Ramirez at Washington University in St Louis

Poster: 387

Tumor-specific mutant antigens (TSMAs) that can be targeted by vaccination were studied in follicular lymphoma patients and led to a first-in-human pilot trial of a personalized TSMA vaccine combined with immunotherapy.

Research conducted with Washington University in St Louis

Abstract Number: e20065

Title: Correlation of PI3K upregulation with NOTCH2 mutations in ibrutinib-resistant mantle cell lymphoma

First Author: Krystle Nomie, PhD, BostonGene

Research conducted with The University of Texas MD Anderson Cancer Center

Abstract Number: e21026

Title: Non-small cell lung cancer: Analysis using mass cytometry and next generation sequencing reveals new opportunities for the development of personalized therapies

First Author: Susan Raju Paul, MBBS, Vaccine and Immunotherapy Center, Massachusetts General Hospital

Research conducted with Massachusetts General Hospital

Abstract Number: e17106

Title: Integrated single-cell spatial multi-omics of intratumor heterogeneity in renal cell carcinoma

First Author: James Hsieh, MD, PhD at Washington University in St. Louis

Research conducted with Washington University in St Louis

Abstract Number: e17506

Title: Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome

First Author: Eric H. Kim, MD at Washington University in St. Louis

Research conducted with Washington University in St Louis

*Abstracts to be presented as posters at the 2020 ASCO Annual Virtual Meeting from May 29-31, 2020

About BostonGene Corporation

BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGenes unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGenes mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005217/en/

Link:
BostonGene Announces Acceptance of Abstracts to the Annual Meeting of the American Society of Clinical Oncology 2020 - BioSpace

Read More...

Trump promises coronavirus vaccine by end of the year, but his own experts temper expectations – KXXV News Channel 25

Monday, May 18th, 2020

President Donald Trump is doubling down on his claim that Americans could see a vaccine for the novel coronavirus by the end of the year.

"Another essential pillar of our strategy to keep America open is the development of effective treatments and vaccines as quickly as possible. I want to see if we can do that very quickly," Trump said Friday at an event to highlight his administration's effort to expedite a vaccine, dubbed "Operation Warp Speed." "When I say 'quickly,' we're looking to get it by the end of the year if we can. Maybe before."

But the Trump administration's own medical and scientific experts leading the race to develop a vaccine routinely cast doubt on that timeline.

On Friday, the president tapped Moncef Slaoui, a former pharmaceutical executive, to lead Operation Warp Speed. Even he concedes the goal is formidable.

"Frankly, 12-18 months is already a very aggressive timeline," Slaoui, the former CEO of GlaxoSmithKline, said in an interview with The New York Times. He said he was in agreement with Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Disease, about the challenge that timeline poses.

Still, Slaoui, the former CEO of GlaxoSmithKline, did say mass producing a vaccine by January 2021 is a "credible objective." Slaoui maintained he would not have agreed to head up the White House's effort if he did not think Trump's goals were attainable.

Since the beginning of the coronavirus crisis, Fauci has frequently cited the 12- to 18-month timeline. He delivered a reality check at a Senate hearing Tuesday when he said having a vaccine for the start of the next school year is not possible.

"Even at the top speed we're going, we don't see a vaccine playing in the ability of individuals to get back to school this term," Fauci said.

But when Sen. Mitt Romney, R-Utah, pressed Fauci on the likelihood of developing a vaccine within in a year or two, Fauci was said it's "not a long shot."

"I think it's clearly much more likely than not that somewhere within that time frame we will get a vaccine for this virus," he said.

But Dr. Rick Bright, the former head of the Biomedical Advanced Research and Development Authority, emphasized to the House Energy and Commerce's Subcommittee on Health Thursday that such a timeline would be unprecedented.

"Normally it takes up to 10 years to make a vaccine. We've done it faster in emergency situations, when we had starting material in the freezer for Ebola, but for a novel virus, this actually hasn't been done yet that quickly," Bright said. "A lot of optimism is swirling around a 12- to 18-month time frame. If everything goes perfectly -- we have never seen everything go perfectly.

"I still think 12 to 18 months is an aggressive schedule, and I think it's going to take longer than that to do so."

On Friday, Defense Secretary Mark Esper echoed the president's claims that the vaccine will be ready in record time.

"We will deliver by the end of this year a vaccine, at scale, to treat the American people and our partners abroad," Esper vowed at the "Operation Warp Speed" event.

But the Pentagon's chief spokesperson, Jonathan Hoffman, told reporters hours later that the timeline is more like a goal than a certainty.

"You set a goal, you have confidence that you're going to put the resources to it to obtain that goal. And I think that's what the secretary, that's what the president, are saying is that we have a goal," Hoffman said.

Currently there are more than 100 vaccines being studied, and at least eight of those have already progressed outside the laboratory and into human studies, according to the World Health Organization. The furthest along include candidates from the University of Oxford, Pfizer, Moderna Therapeutics, Inovio Pharmaceuticals and China's CanSino Biologics.

Many of these vaccines use different technology -- some new to vaccine science -- and experts still don't know which is the most likely to work.

Other experts interviewed by ABC News have agreed with Bright, saying that developing a vaccine within a 12-month time frame could mean throwing normal scientific standards out the window, but added that a vaccine could be available by the new year if everything goes perfectly.

"It is not impossible," said Paul Duprex, Ph.D., director of the Center for Vaccine Research and professor of microbiology and molecular genetics at the University of Pittsburgh. "It's of course very aggressive -- but it is possible."

"You'd have to be lucky," said Dr. Paul Offit, co-inventor of the rotavirus vaccine, who sits on the Food and Drug Administration's vaccine advisory committee. "It would be remarkable, but not completely ridiculous."

Bright also warned Thursday of potential supply chain shortages for necessary materials like vials, needles and syringes, as well as the buffers and solutions used to make the vaccine.

Bright highlighted the importance of a plan to distribute the vaccine, given enough doses for every American will not be ready at once. Creating that plan is one of the goals of Operation Warp Speed.

"If you can imagine this scenario this fall or winter or maybe early next spring when vaccine becomes available; there is no one company that that can produce enough for our country and for the world," Bright said. "It's going to be limited supplies. We need to have a strategy and plan in place now to make sure we can not only fill that vaccine, make it, distribute it, but administer it in a fair and equitable plan."

Trump said Friday his administration is working on a plan to distribute the vaccine, including ramping up production of necessary materials and supplies. The president even mentioned on Thursday the military could be involved in the effort to dispense the vaccine.

"Operation Warp Speed is also making the necessary preparations to distribute these lifesaving treatments at scale. So, we are talking about massive numbers, so that millions of Americans will quickly have access to them," Trump said.

Efforts are already underway to mass produce vaccines that are still being studied, in an attempt to have doses ready to be administered as soon as possible.

"We're going to make production at risk, means we'll start putting hundreds of millions of dollars of federal government money into the development and production of vaccine doses before we even know it works. So that when we do ... ultimately get an effective and safe vaccine, that we will have doses available to everyone who needs it in the United States," Fauci said Tuesday.

Read the original:
Trump promises coronavirus vaccine by end of the year, but his own experts temper expectations - KXXV News Channel 25

Read More...

Monitoring Wastewater Could Be Key to Tracking a Second Wave of COVID-19 – Technology Networks

Monday, May 18th, 2020

As the UK starts to ease its lockdown restrictions, researchers are developing new techniques that could enable wastewater to be used to locate new infection hotspots or to help track a second wave of the coronavirus pandemic.

The research, which is bringing together some of the worlds leading experts on wastewater management, is establishing a range of new standardised procedures to identify the virus in wastewater and provide a picture of how COVID-19 is spreading, without the need for testing individuals.

Brought together by the Water Research Foundation, the international group is:

- Developing best-practices and standardised procedures for collecting and storing water samples

- Developing best-practices for using molecular genetics tools to identify levels of COVID-19 in wastewater samples

- Developing recommended approaches for using levels of COVID-19 in water samples to inform trends and estimates of the spread of the virus in communities

- Developing strategies to communicate the implications of environmental surveillance results with the public health community, elected officials, wastewater workers, and the public

One key component in enabling wastewater to be used to help track the spread of the pandemic is to monitor the presence of COVID-19 virus genetic markers. Professor Vanessa Speight from the University of Sheffields Department of Civil and Structural Engineering is co-leading efforts to establish new data analysis and modelling techniques that can be used to reliably interpret the data collected from wastewater samples.

These techniques could help create a more accurate map of how the virus is spreading as well as the emergence of a second wave of the pandemic. The use of wastewater monitoring for COVID-19 virus occurrence offers a quick way to get an integrated picture of the level of infection across a whole community without the need for testing individuals.

Professor Speight, who is also a member of the Sheffield Water Centre at the University, which works with industry to solve major challenges in the water sector, said: There is great potential for wastewater to provide valuable information about the occurrence of COVID-19 across communities. But given that this is a very new field of investigation, we have identified a number of areas where future research efforts should be concentrated to maximise the value of this data.

The group of water experts recently gathered virtually for an International Water Research Summit to share recommendations and exchange early findings.

Each team is now undertaking their research with a view to having results that could be used to help track a second wave of COVID-19 or other future pandemics.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

More:
Monitoring Wastewater Could Be Key to Tracking a Second Wave of COVID-19 - Technology Networks

Read More...

Waldoboro native discusses how she has trained many on the frontlines of COVID-19 testing – PenBayPilot.com

Monday, May 18th, 2020

EAST LANSING, Mich. While the ongoing COVID-19 pandemic continues to affect the world, one Waldoboro native has stepped to the frontlines of the pandemic and trained numerous individuals currently working on COVID-19 testing.

Dr. Rachel Morris, now a teaching specialist and and graduate program director at Michigan State University, volunteered to be a COVID-19 contact tracer and, through her teaching, prepared students for similar work.

Morris, who is also helping by sewing many face masks,attended a now defunct private Christian high school in Warren before earning from the University of Maine at Augusta an associates degree in medical laboratory science and a bachelors degree in biology.

She also earned a doctorate degree in biological sciences, with a concentration in microbiology, from Marquette University. Her postdoctoral research and training was completed through the University of Michigan Medical School (internal medicine and infectious diseases) and Michigan State Universitys Department of Microbiology and Molecular Genetics.

Living in the Midcoast until the age of 35, Morris noted being a Mainer has influenced her life in a variety of ways, including some she likely does not even recognize.

I guess I would say it has made me a strong person and an independent thinker, she stated, while crediting her time at UMA as shaping her into the professional she is today.

The field of science has captivated Morris since she was a young child.

I was always out in nature exploring things and doing experiments of one kind or another, she said.

Interested in medicine but favoring bench science, she trained as a medical laboratory technician at UMA right after high school and worked at the Togus Veterans Administration Medical Center.

After pausing her education to have children and do some part-time tutoring and teaching, she returned to UMA to earn her bachelors degree in biology, believing she was going to be a high school science teacher.

Her advisor, Dr. Peter Milligan, asked her to join his new research lab. Morris was hooked on microbiology research and had discovered a new passion teaching and conducting research. (Her areas of research interest at Michigan State includethe microbial ecology of anaerobic wastewater treatment, the physiology and ecology of bacteria in low oxygen environments, diagnostic microbiology, and faculty development.)

After earning her doctorate degree, a requirement for her newfound passion, and postdoctoral training, she accepted a position on staff at Michigan State University in 2014. The job, she said, seems to tie all her experience together.

As an educator at Michigan State, Morris teachespathology, molecular diagnostics, and writing, while serving as the graduate school program director for the universitysBiomedical Laboratory Diagnostics (BLD) program.

The program is tasked, according to Morris, with training individuals toperform human diagnostic testing in hospital laboratories, public health labs, and reference labs.

Many of Morris previous students, who are Medical Laboratory Scientists, are performing COVID-19 testing.

Morris offered one note of clarification about COVID-19 testing.

The drive-through testing process many may have heard of is really drive-through specimen collection.

The swabs are not being tested for the virus by the people who collect them at these sites, she said. They are put into a transport medium that stabilizes the virus and sent to a laboratory for testing.

To become a MLS, you need a bachelor's degree which includes a lot of science, lab classes, and math, Morris detailed. These rigorous courses include multiple classes in things like statistics, chemistry, microbiology, hematology, immunology, and molecular diagnostics. You must also complete a laboratory internship in an actual hospital lab setting that lasts about six months to a year. Most people who complete this training sit for a board of certification exam overseen by the American Society for Clinical Pathology, and they must complete continuing education to maintain their certification.

Becoming a MLS requires an abundance of training, Morris noted, while adding she is very proud of her students.

I taught them that the patient comes first, and they are out on the front lines living it right now, she said.There are now many types of tests for the virus on the market with different methodologies. My students are qualified to run them all, but some are designed to be run by people with less training than my students have. Some of my students oversee this testing, however, to assure that they produce quality results.

Talk of contact tracers has been a recurring point of Maine CDC Director Dr. Nirav Shahs weekday press briefings, where he discusses the latest pandemic updates in the state.

What exactly is a contact tracer and what are their responsibilities?

The volunteers work with local public health departments, Morris detailed, and talk to people who have been reported to have had contact with an individual that has tested positive for COVID-19.

These people, who may now be at risk for COVID-19 themselves, need information, she explained. So, they are contacted, told that they have been in contact with someone with the virus, and provided with information for what they should do next. This whole process maintains the confidentiality of the person who tested positive and their contacts. In general, people are going to be asked to self-isolate and watch for symptoms. They are told what to do if they do have symptoms and are also provided with resources for any sort of help that they might need related to their situation.

Thanks to her professional background, Morris decided to undergo training necessary to be a COVID-19 contact tracer in Michigan.

Despite completing the training, she has not had the opportunity to participate, as of yet, due, in part, to needing to assist her colleagues at Michigan State shift to virtual teaching.

It has been quite a challenge for educators all over the nation to transition away from face-to-face instruction, Morris said.

As the director of the graduate school program that offers three online degrees, Morris holds virtual instruction most semesters and virtual education is constantly on her mind, even before the pandemic forced virtual education to become more prevalent.

I have also had some training in this area, so when the switch to remote learning happened I had three hours from when I found out until my first online class meeting it was pretty easy for me, she stated. But for others with less experience and for the students who didnt sign up for that huge change, it was more difficult.

As part of her work in assisting her colleagues shift to virtual education, she has answered questions, shared tutorials on using technology in teaching and helped lead a week-long workshop for colleagues moving entire programs to virtual learning for Michigan States summer term.

Morris is also the co-host of a podcastSpeaking Science that aims to translate the science affecting ones daily life.

Click here to listen to the episodes.

As a professor, Morris, naturally, is also tasked with helping her students adapt and cope with their educational, and life, experiences being altered by the pandemic.

I will be getting additional training and continuing to provide help and guidance for my peers on the MSU faculty over the summer, she said. I give out advice to the broader community now and then on Twitter. I was pretty excited when the learning management system that we use asked if they could use some of my advice in their advertising materials.

Morris noted she hopes to assist the local health department during the summer.

Though she has not yet been able to participate in the contact tracing program, she stressed it is vital that those who are qualified, and able to, participate as a contact tracer do so in order to control the virus and restore some sense of normalcy.

Knowledge is power in this situation, especially until we have a treatment or vaccine, she said. We need to have enough testing and contact tracing to help isolate people who may pass on the virus to others. In this way, we can limit the spread of the SARS-Cov-2 virus.

Speaking on why she opted to volunteer, Morris said it was a logical decision given her background.

I volunteered because, while I don't do diagnostic testing anymore, I have been trained in things like medical confidentiality and patient interaction, and so it seemed a logical thing to do when the governor put out the call, she said. We all want to get our country running again, at least as much as possible. I want to do what I can to help.

Asked to provide final words of wisdom amid the pandemic, Morris offered:Wash your hands. Don't touch your face or other people. Listen to [Director of National Institute of Allergy and Infectious Diseases] Dr. [Anthony] Fauci. Be kind.

More:
Waldoboro native discusses how she has trained many on the frontlines of COVID-19 testing - PenBayPilot.com

Read More...

UI research entity distributes antibodies to those studying COVID-19 – UI The Daily Iowan

Monday, May 18th, 2020

The Developmental Studies Hybridoma Bank housed at the University of Iowa distributes and stores antibodies for biological research.

The Developmental Studies Hybridoma Bank, housed at the University of Iowa, stores and distributes antibodies that now are being distributed to help researchers study the novel coronavirus.

Originally created by the National Institutes of Health 34 years ago, the Developmental Studies Hybridoma Bank is a self-funded entity that keeps antibodies, proteins produced by the immune system to fight viruses and diseases, for companies worldwide for basic research.

David Soll, the banks director, brought the entity to the UI from Johns Hopkins University. The entity sends about 60,000 samples a year worldwide for biological and cancer research, he said.

The bank sells its antibodies to researchers for $40, Soll said. None of the antibodies can be used for commercial purposes, however, as the bank doesnt own the antibodies, it just stores them for researchers, he said.

Although it did not have antibodies specifically for COVID-19, the bank did have a large number of antibodies that react similarly to the coronavirus and could allow researchers to study the interaction between the virus and human cells, Soll said.

The antibodies the bank has can help researchers study the cytokines proteins that are important to cell signaling which sometimes cause the body to react violently to a virus, he said.

We have a very large footprint inside the research community, and the way we do it is we dont own any of the antibodies, people from all over the world bank their antibodies with us, Soll said.

The bank also makes antibodies, Soll said. Its currently producing plasmids and then inserting a piece of DNA into them that codes them for targeted viruses, he added.

The plasmids are injected into mice, Soll said, and then the mouse will make the proteins of the virus and then make antibodies against it.

RELATED: University of Iowa molecular genetics researcher studying COVID-19 testing methods to alleviate test shortages

Diane Slusarski, UI biology department head, is a member of the Developmental Studies Hybridoma Banks advisory board, which meets with Soll to discuss the entitys inventory and work.

The bank provides antibodies for biomedical research and basic research at a good price, Slusarski said. This allows basic research to move forward, she said, because often the budgets arent very large.

The bank has accumulated a lot of antibodies over its years of operations, which makes it so they have the immune response for viruses as well as the antibodies, she said.

The immune responses can be used to understand how the body reacts to other viruses even though the bank doesnt have coronavirus specific antibodies, Slusarski said.

Because the bank is housed at the UI, the biology department is able to give graduate students an opportunity to learn what it takes to make an antibody, Slusarski said.

Now youre going to have people interested in these immune [antibodies] that they have, Slusarski said. So theyre very strategic in looking at how we can help.

Kevin Campbell, UI professor of molecular physiology and biophysics, keeps some of the antibodies his lab has created in the bank.

When he first started teaching at the UI, Campbell said his lab made proteins to study muscles and have been helpful in the productivity of his work, which focuses on muscle physiology and muscular dystrophy.

Campbell said the bank functions as a storage facility to prevent researchers from losing their antibodies if a freezer fails them, and the bank grows the supply of the antibody.

The biggest [benefit] is that now you can make [the antibodies] available to everybody in the world doing research, he said. So that really frees you up from having to send the antibodies out to laboratories.

Continued here:
UI research entity distributes antibodies to those studying COVID-19 - UI The Daily Iowan

Read More...

Researcher Qing Wang Arrested, Allegedly Failed To Disclose China Ties – NPR

Monday, May 18th, 2020

The FBI claims Dr. Qing Wang received more than $3.6 million in grants from the NIH while also collecting money for the same research from the Chinese government. Jose Luis Magana/AP hide caption

The FBI claims Dr. Qing Wang received more than $3.6 million in grants from the NIH while also collecting money for the same research from the Chinese government.

A former Cleveland Clinic Foundation doctor was arrested Wednesday and appeared in court on Thursday on charges of wire fraud and making false claims to obtain millions in federal grant funding.

It is the latest move in a federal crackdown on alleged participants in China's Thousand Talents Plan. The government believes the program may recruit U.S.-based scientists and researchers to steal intellectual property and scientific advances paid for with American funding.

The FBI claims Qing Wang, a U.S. citizen born in China, lied to receive more than $3.6 million in grants from the National Institutes of Health while also collecting money for the same research from the Chinese government.

"This is not a case of simple omission," FBI Cleveland Special Agent in Charge Eric Smith said in a statement.

Wang knowingly withheld information that he was employed and served as Dean of the College of Life Sciences and Technology at the Huazhong University of Science and Technology, according to Smith.

"Dr. Wang deliberately failed to disclose his Chinese grants and foreign positions and even engaged in a pervasive pattern of fraud to avoid criminal culpability," Smith said.

Had he revealed the connection, the FBI and Department of Justice say the doctor and his research group at the clinic would have been denied the NIH grants.

Officials at the Cleveland Clinic said Wang was fired after his ties to China were uncovered.

"Cleveland Clinic has cooperated fully with the NIH and with federal law enforcement as they conducted their own investigations into these same subjects and will continue to do so," it said in a statement.

Wang's work is dedicated to molecular medicine and the genetics of cardiovascular and neurological diseases.

As a result of his alleged participation in the Thousand Talents Plan, the Justice Department asserts Wang received $3 million in research support to improve operations at Huazhong University. In addition to a salary, he allegedly benefited from "free travel and lodging for his trips to China, to include a three-bedroom apartment on campus for his personal use."

The question of whether or not Wang and other academics are serving as spies for the Chinese government is one of the issues at the heart of President Trump's trade war with China.

The doctor's arrest comes just days after Dr. Xiao-Jiang Li, a former Emory University professor, pleaded guilty and was sentenced for failing to report foreign income from Chinese universities on his tax returns. Li is also accused of participating in the TTP.

The same day, a professor from the University of Arkansas, Dr. Simon Saw-Teong Ang, was arrested on charges of wire fraud for allegedly failing to disclose his ties to the Chinese government despite being required to do so as a recipient of grant money from NASA.

Robert Wells, acting assistant director of the FBI's Counterintelligence Division, said the cases demonstrate "Chinese government-supported talent plans continue to encourage people, regardless of nationality, to commit crimes, such as fraud to obtain U.S. taxpayer-funded research."

"The FBI and our partners will continue to rigorously investigate these illegal activities to protect our government, educational, and research institutions," Wells added.

Read this article:
Researcher Qing Wang Arrested, Allegedly Failed To Disclose China Ties - NPR

Read More...

Intriguing Genetics That Flipped the Food Chain to Allow Carnivorous Plants to Hunt Animals – SciTechDaily

Monday, May 18th, 2020

Plants can produce energy-rich biomass with the help of light, water and carbon dioxide. This is why they are at the beginning of the food chains. But the carnivorous plants have turned the tables and hunt animals. Insects are their main food source.

A publication in the journal Current Biology now sheds light on the secret life of the green carnivores. The plant scientist Rainer Hedrich and the evolutionary bioinformatician Jrg Schultz, both from Julius-Maximilians-Universitt (JMU) Wrzburg in Bavaria, Germany, and their colleague Mitsujasu Hasebe from the University of Okazaki (Japan) have deciphered and analyzed the genomes of three carnivorous plant species.

They studied the Venus flytrap Dionaea muscipula, which originates from North America, the globally occurring waterwheel plant Aldrovanda vesiculosa and the spoon-leaved sundew Drosera spatulata, which is widely distributed in Asia.

The genomes of the carnivorous plants Venus flytrap, spoon-leaved sundew and waterwheel (from left) are decoded. Credit: Dirk Becker and Snke Scherzer / University of Wrzburg

All three belong to the sundew family. Nevertheless, they have each conquered different habitats and developed their own trapping mechanisms. In Dionaea and Aldrovanda, the ends of the leaves are transformed into folding traps. The sundew, on the other hand, attaches its prey to the leaf surface with sticky tentacles.

The first thing the international research team found out was that, despite their different lifestyles and trapping mechanisms, Venus flytrap, sundew and waterwheel have a common basic set of genes that are essential for the carnivorous lifestyle.

The function of these genes is related to the ability to sense and digest prey animals and to utilize their nutrients, explains Rainer Hedrich.

We were able to trace the origin of the carnivory genes back to a duplication event that occurred many millions of years ago in the genome of the last common ancestor of the three carnivorous species, says Jrg Schultz. The duplication of the entire genome has provided evolution with an ideal playing ground for developing new functions.

To their surprise, the researchers discovered that the plants do not need a particularly large number of genes for carnivory. Instead, the three species studied are actually among the most gene-poor plants known. Drosera has 18,111, Dionaea 21,135 and Aldrovanda 25,123 genes. In contrast, most plants have between 30,000 and 40,000 genes.

How can this be reconciled with the fact that a wealth of new genes is usually needed to develop new ways of life? This can only mean that the specialization in animal food was accompanied by an increase in the number of genes, but also a massive loss of genes, concludes developmental biologist Hasebe.

Most of the genes required for the insect traps are also found in slightly modified form in normal plants. In carnivorous plants, several genes are active in the trapping organs, which in other plants have their effect in the root. In the trapping organs, these genes are only switched on when the prey is secure, explains Hedrich. This finding is consistent with the fact that the roots are considerably reduced in Venus flytrap and sundew. In the waterwheel they are completely absent.

The researchers now have an insight into the evolution of carnivory in plants and hold three blueprints for this particular way of life in their hands. Their next goal is to gain an even better understanding of the molecular basis of the trapping function.

We have found that the Venus flytrap counts the electrical stimuli triggered by the prey, can remember this number for a certain time and finally makes a decision that corresponds to the number, says Hedrich. Now it is important to understand the biophysical-biochemical principle according to which carnivorous plants count.

Reference: Genomes of the Venus Flytrap and Close RelativesUnveil the Roots of Plant Carnivory by Gergo Palfalvi, Thomas Hackl, Niklas Terhoeven, Tomoko F. Shibata, Tomoaki Nishiyama, Markus Ankenbrand, Dirk Becker, Frank Frster, Matthias Freund, Anda Iosip, Ines Kreuzer, Franziska Saul, Chiharu Kamida, Kenji Fukushima, Shuji Shigenobu, Yosuke Tamada, Lubomir Adamec, Yoshikazu Hoshi, Kunihiko Ueda, Traud Winkelmann, Jrg Fuchs, Ingo Schubert, Rainer Schwacke, Khaled Al-Rasheid, Jrg Schultz, Mitsuyasu Hasebe, Rainer Hedrich, 14 May 2020, Current Biology.DOI: 10.1016/j.cub.2020.04.051

Read this article:
Intriguing Genetics That Flipped the Food Chain to Allow Carnivorous Plants to Hunt Animals - SciTechDaily

Read More...

Good Science Is Good Science – Boston Review

Monday, May 18th, 2020

Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image: National Institute of Allergy and Infectious Diseases, Flickr

For the sake of both science and action in the COVID-19 pandemic, we need collaboration among specialists, not sects.

The Brazilian-British biologist Peter Medawar won the Nobel Prize in 1960 for his study of acquired immune tolerance. Beyond his scientific work, he was also a gifted writer and expositor of scientific culture. One of the many treasures of his Advice to a Young Scientist (1979) is a passage in his chapter on Aspects of Scientific Life and Manners where he discusses techniques used in the hope of enlarging ones reputation as a scientist or diminishing the reputation of others by nonscientific means.

One such trick, Medawar writes, is to affect the possession of a mind so finely critical that no evidence is ever quite good enough (I am not very happy about. . . .; I must say I am not at all convinced by. . . .). After all, as he writes in a different passage, no hypothesis in science and no scientific theory ever achieves . . . a degree of certainty beyond the reach of criticism or the possibility of modification.

Scientists must resist the temptation to excessive skepticism: the kind that says no evidence is ever quite good enough. Instead they should keep their eyes open for any kind of information that can help them solve problems.

I share Medawars pragmatic vision of scientific reasoning. Scientists must resist the temptation to excessive skepticism: the kind that says no evidence is ever quite good enough. Instead they should keep their eyes open for any kind of information that can help them solve problems. Deciding, on principle, to reject some kinds of information outright, or to consider only particular kinds of studies, is counterproductive. Instead of succumbing to what Medawar calls habitual disbelief, the scientist should pursue all possible inputs that can sharpen ones understanding, test ones preconceptions, suggest novel hypotheses, and identify previously unrecognized inconsistencies and limitations in ones view of a problem.

This conception of science leads me to disagree with some elements of the philosopher of medicine Jonathan Fullers recent essay about two sects within epidemiology, defined by what kinds of evidence they consider meaningful and how they think decisions should be made when evidence is uncertain. Fuller sees in the contrast two competing philosophies of scientific practice. One, he says, is characteristic of public health epidemiologists like me, who are methodologically liberal and pragmatic and use models and diverse sources of data. The other, he explains, is characteristic of clinical epidemiologists like Stanfords John Ioannidis, who draw on a tradition of skepticism about medical interventions in the literature of what has been known since the 1980s as evidence-based medicine, privilege gold standard evidence from randomized controlled trials (as opposed to mere data), and counsel inaction until a certain ideal form of evidenceEvidence with a capital Ejustifies intervening.

Fuller rightly points out that this distinction is only a rough approximation; indeed, there are many clinical epidemiologists who do not share the hardline skepticism associated with the most extreme wing of the evidence-based medicine community. But the distinction is also misleading in a subtle way. If the COVID-19 crisis has revealed two competing ways of thinking in distinct scientific traditions, it is not between two philosophies of science or two philosophies of evidence so much as between two philosophies of action.

If the COVID-19 crisis has revealed two competing ways of thinking, it is not between two philosophies of science or two philosophies of evidence so much as between two philosophies of action.

In March, as health systems in Wuhan, Iran, and Northern Italy teetered under the weight of COVID-19 cases, Ioannidis cautioned that we really didnt know enough to say whether a response was appropriate, warning of a once-in a-century evidence fiasco and suggesting that the epidemic might dissipate on its own. (I replied to that argument, explaining why we do know enough to act decisively against this pandemic.) To my knowledge, Ioannidis has never stated that early interventions should have been avoided, but by repeatedly criticizing the evidence on which they were based, he gives that impression.

On the question of how we interpret evidence, Fuller concludes that to understand the scientific disagreements being aired about COVID-19, we need to blend the insights of each camp. Cooperation in society should be matched by cooperation across disciplinary divides, he writes. I dont understand what this kind of bothsidesism means when one side is characterized as accepting many types of evidence and the other as insisting on only certain kinds. On the question of how we should make decisions under uncertainty, of course more data are better. But decisions are urgent and must be made with the evidence weve got.

This is not to deny that there are different and valuable perspectives on epidemiology. Like any other field, there are many specialties and subspecialties. They have different methods for how they study the world, how they analyze data, and how they filter new information. No one person can keep up with the flood of scientific information in even one field, and specialization is necessary for progress: different scientists need to use different approaches given their skills, interests, and resources. But specialization should not lead to sectsin this case, a group of scientists who accept only certain kinds of evidence and too rigidly adhere to a philosophy of non-interventionism.

Infectious disease epidemiologists must embrace diverse forms of evidence by the very nature of their subject. We study a wide range of questions: how and under what conditions infectious diseases are transmitted, how pathogens change genetically as they spread among populations and across regions, how those changes affect our health, and how our immune systems protect us and, sometimes, make us vulnerable to severe illness when immune responses get out of control. We also seek to understand what kinds of control measures are most effective in limiting transmission. To understand these issues for even one type of diseasesay, coronavirus diseasesrequires drawing on a wide range of methodologies and disciplines.

On the question of how we should make decisions under uncertainty, of course more data are better. But decisions are urgent and must be made with the evidence weve got.

We consider evidence from classical epidemiological studies of transmission in households and other settings. We consider immunological studies that show us how markers of immunity develop, whether they protect us against future disease, and how particular markers (say a certain type of antibody directed at a certain part of the virus) change infection and mortality rates. We consider molecular genetics experiments, including those conducted in animal models, that tell us how changes in a viruss genome affect the course of disease. We consider evolutionary patterns in the viruss genetic code, seasonal patterns in its transmission and that of other related viruses, and observational studies of the risk factors and circumstances favoring transmission. And, of course, we also consider randomized trials of treatments and prevention measures, when they exist, as we seek to understand which interventions work and which ones may do more harm than good.

The upshot is that, done well, epidemiology synthesizes many branches of science using many methods, approaches, and forms of evidence. No one can be expert in all of these specialties, and few can even be conversant in all of them. But a scientist should be open to learning about all of these kinds of evidence and more.

Thinking about evidence from diverse specialties is critical not only for weighing evidence and deciding how to act but also for developing hypotheses that, when tested, can shed light across specialties. Appropriate humility dictates that molecular virologists should not assume they are experts in social epidemiology, and vice versa. To say Im a virologist, so Im not going to account for any findings from social epidemiology in my work gives up the chance to understand the world better.

Heres an example. In the case of a new virus like SARS-CoV-2, the fact that socioeconomically disadvantaged people get sick more often than the wealthy gives clues, which we dont yet know how to interpret, about the way the virus interacts with hosts. It would be informative to a virologist to distinguish the following two hypotheses (among others): (a) exposure to high doses of virus tends to cause severe disease, and disadvantaged people are often exposed to higher doses due to confined living and working conditions, or (b) comorbidities such as heart disease and obesity are higher among disadvantaged people, and lead to more severe outcomes. Of course, either, both, or neither of these hypotheses may turn out to be important explanations, but the canny virologist should wonder and think about how to distinguish them experimentally and test results against data from human populations. Reciprocally, a canny social epidemiologist should look to virological studies for clues about why COVID-19, like so many other illnesses, disproportionately harms the least advantaged in our society.

Done well, epidemiology synthesizes many branches of science. No one can be expert in all of these specialties, and few can even be conversant in all of them, but a scientist should be open to learning about all of these kinds of evidenceand more.

In practice, virologists, immunologists, and epidemiologists are different specialists who often work far apart and almost never attend each others seminars. I do not think we should spend all our time learning each others disciplines. But I do think that a scientist who genuinely wants to solve an important problem should be open to evidence from many sources, should welcome the opportunity to expand their list of hypotheses, and should seek to increase their chances both of making a novel contribution to their field and of being right. Central to this effort is considering information from diverse kinds of studies performed by people with diverse job titles in diverse departments of the universityas well as their diverse forms of data and argumentation.

When we move from the realm of understanding to the realm of intervention, the need for openness to different sources of evidence grows further. In some cases, like whether to use a drug to treat infection or whether to use a mask to prevent transmission, we can draw on evidence from experiments, sometimes even randomized, controlled, double-blind experiments. But in deciding whether to impose social distancing during an outbreak of a novel pathogenand in thinking about how the course of the epidemic might play outit would be crazy not to consider whatever data we can, including from mathematical models and from other epidemics throughout history. With infectious diseases, especially new and fast-spreading pandemics, action cant wait for the degree of evidentiary purity we get from fully randomized and controlled experiments, or from the ideal observational study. At the same time, we must continue to improve our understanding while we act and change our actions as our knowledge changesleaving both our beliefs and our actions open, as Medawar says, to the reach of criticism and the possibility of modification.

Where does the skepticism so characteristic of the evidence-based tradition come from? One reason may be the habits and heuristics we absorb from textbooks, colleagues, and mentors.

In supervising students and postdocs, inculcating these habits is one of the most challenging, gratifying, and time-consuming parts of scientific trainingfar more than teaching technical skills. Some of these rules of thumb are well suited to science in general and serve us well throughout our careers, no matter the field. Among these are workaday but important heuristics like: consider alternative hypotheses; look at raw data whenever possible before looking at processed data; and repeat experiments, especially those whose results surprise you. Indeed, these heuristics can be summarized as a form of intense skepticism directed at ones own work and that of ones team: find all the flaws you can before someone else does; fix those you can and highlight as limitations those which are unfixable. Recently an advanced PhD student said to me: I read your new idea that you shared on Slack this morning and Ive been doing my best all afternoon to break it. It made my day, and made me think I probably had very little left to teach her.

Scientists of all stripes should work together to improve public health, and none should mistake a professional tendency or a specialists rule of thumb for an unshakable epistemological principle.

Other heuristics, however, are more specific to a narrow field and may be ill suited to other contexts. Insisting on gold standard, randomized trial evidence before prescribing drugs to prevent heart attacks or before performing a certain surgical operation may be a good rule of thumb in medicine (though not all physicians or even philosophers agree). But randomized controlled trials are not available for huge swaths of scientific inquiry, and the narrow populations often studied in such trials can limit their applicability to real-world decision making. Nor are they always available when we need them: they require a lot of time and administrative resources to execute (and money, for that matter). Stumping for Evidence is thus useful in many parts of clinical medicine but impractical in many other aspects of science-informed decision making. Applying this doctrine indiscriminately across all areas of science turns the tools of a specialist into the weapons of a sectarian.

This point was appreciated by some of the pioneers of evidence-based medicine: David Sackett, William Rosenberg, J. A. Muir Gray, R. Brian Haynes, and W. Scott Richardson. Evidence-based medicine is not restricted to randomized trials and meta-analyses, they wrote in 1996. It involves tracking down the best external evidence with which to answer our clinical questions. And last week the Oxford professor of primary care Trisha Greenhalgh, another major contributor to this field and author of a popular textbook on evidence-based medicine, suggested that in the realm of social interventions to control the spread of COVID-19, the evidence-based clinical paradigmwaiting for the definitive [randomized controlled trial] before taking actionshould not be seen as inviolable, or as always defining good science.

Indeed, on the question of how we ought to act during an outbreak, two leading epidemiologists in the clinical tradition, Hans-Olov Adami and the late Dimitrios Trichopoulos, argued that the non-interventionist rule of thumb is suitable for chronic, noncommunicable diseases but foolish for fast-moving infectious diseases. In an editorial accompanying an article that showed that the impact of cell phones in causing brain cancer was not large but might be larger than zero, they counseled cautious inaction in regulating cell phones. But they noted this is not how you would reason in the case of a transmissible disease:

There is another lesson to be learned about the alarms that have been sounded about public health during the past few years. When the real or presumed risk involves communicable agents, such as the prions that cause bovine spongiform encephalopathy (mad cow disease), no precaution, however extreme, can be considered excessive. By contrast, for noncommunicable agents, such as radio-frequency energy, the lack of a theoretical foundation and the absence of empirical evidence of a substantial increase in risk legitimize cautious inaction, unless and until a small excess risk is firmly documented.

In my ideal public health world wed have a lot more good sense like that proposed by Adami and Trichopoulos, acting not only on the strength of the evidence we have but on the relative harms of being wrong in each direction. And whether waiting or acting, wed work hard to get the evidence to meet the challenges of skeptics and improve our decision-making, all with an eye to the possibility of criticism and modification Medawar describes.

Here is the original post:
Good Science Is Good Science - Boston Review

Read More...

Sewage could be key to tracking second wave of coronavirus – Irish Examiner

Monday, May 18th, 2020

Scientists are developing ways of using sewage to locate new infection hotspots and track a second wave of Covid-19.

An international group of waste water experts are researching new techniques that could identify the level of infection in a community without the need for testing individuals.

New standardised procedures could identify the virus in waste water and provide a picture of how coronavirus is spreading, the researchers said.

The group, who were brought together by the Water Research Foundation and include engineers from the University of Sheffield, are developing a range of best practices concerning the use of sewage.

These include collecting and storing waste water samples and using molecular genetics tools to identify levels of Covid-19 in sewage samples.

The scientists are also developing recommended approaches for using levels of coronavirus in waste water samples to inform trends and estimates of the spread of the virus in communities and developing strategies to communicate the implications of the results with the public.

There is great potential for waste water to provide valuable information about the occurrence of Covid-19 across communities

Professor Vanessa Speight, from the University of Sheffields Department of Civil and Structural Engineering, is researching techniques to reliably interpret the data collected from sewage samples.

Her results could help create a more accurate map of how the virus is spreading and show the emergence of a second wave of the pandemic.

She said: There is great potential for waste water to provide valuable information about the occurrence of Covid-19 across communities.

On Monday, Prime Minister Boris Johnson said a new alert system to monitor the threat posed by coronavirus could eventually identify local flare-ups if Covid-19 is detected in the waste water from a local area.

The PMs official spokesman said: Some studies have been carried out overseas on this and I think it is something we are looking at as a possible way of seeing if you could track the rate of infections locally.

The Downing Street spokesman said officials are investigating whether sewage samples would allow them to track if the virus is more prevalent in some parts of the country than in others.

Experts said some countries are testing waste water to see if there is infection in the community.

We are actively engaging with the research community and Government scientific advisers to investigate whether monitoring waste water could be used as a way of tracking the prevalence of the virus

And, while there is no evidence of the live virus being found in sewage or that the virus has been spread through sewerage systems, one study from the Netherlands found viral genetic material in waste water samples several weeks before the first case was detected.

A spokesman from the Department for Environment, Food and Rural Affairs (Defra) said: We are actively engaging with the research community and Government scientific advisers to investigate whether monitoring waste water could be used as a way of tracking the prevalence of the virus.

Last month, scientists from Newcastle University said they were collaborating with Spanish academics to monitor sewage in their local networks in both countries to estimate the prevalence of Covid-19 in north-east England and across Spain.

The rest is here:
Sewage could be key to tracking second wave of coronavirus - Irish Examiner

Read More...

WHITEHALL ANALYTICA THE AI SUPERSTATE: Part 2 Is COVID-19 Fast-Tracking a Eugenics-Inspired Genomics Programme in the NHS? – Byline Times

Monday, May 18th, 2020

Nafeez Ahmed explores the troubling implications and assumptions of the Governments AI-driven gene programme.

In Part 1 of this investigation, I looked at how the convergence of an AI Superstate and corporate interests with health data lies at the heart of a new frontier for profit and surveillance. But the Governments response during the COVID-19 pandemic has revealed something even more profoundly disturbing: a fascination with genomics which moves from a merely descriptive tool to something so prescriptive it verges on eugenics.

The NHSX app is simply one project with a questionable design which appears to result from the Governments much wider project to remake the NHS.

At the core of the new NHSX AI drive is the goal of predictive, preventive, personalised and participatory medicine, according to an NHSX document published in October 2019. Pivotal to this AI-driven transformation is genetics:

Key to unlocking the benefits of precision medicine with AI is the use of genomic data generated by genome sequencing. Machine learning is already being used to automate genome quality control. AI has improved the ability to process genomes rapidly and to high standards and can also now help improve genome interpretation.

The NHS Genomic Medicine Service is starting with a focus on cancer, rare and inherited diseases,but its broader goal is far more comprehensive. Initially, the hope is that genomics will expand to cover other areas, such as pharmacogenomics, which looks at how an individuals genes influence a particular biological process that mediates the effects of a medicine, according to The Pharmaceutical Journal.

But the end-goal is to convert the NHS into a health service oriented fundamentally around the role of genetics in disease. The aspiration is that from 2020, and by 2025, genomic medicine will be an embedded part of routine care to enable better prediction and prevention of disease and fewer adverse drug reactions. The GMS aims to complete five million genomic analyses and five million early disease cohorts over the next five years.

By 2025, genomic technologies will be embedded through multiple clinical pathways and included as a fundamental part of clinical training. As a result, it is hoped that there will be a new taxonomy of medicine based on the underlying drivers of disease.

But, this entire premise is deeply questionable. There is little evidence that the underlying drivers of disease are primarily genetic.

Last December, a study in the journal PLOS One found that genetics usually explains no more than 5-10% of the risk for several common diseases. The study examined data from nearly 600 earlier studies identifying associations between common variations in the DNA sequence and more than 200 medical conditions. But its conclusion was stark: more than 95% of diseases or disease risks including Alzheimers, autism, asthma, juvenile diabetes, psoriasis, and so on could not be predicted accurately from the DNA sequence. A separate meta-analysis of two decades of DNA science corroborated this finding.

The implication is startling: that the entire premise for the billions of pounds this Government is investing in building a new privatised NHS infrastructure for AI-driven genomic medicine is scientifically unfounded.

The obsession with genetics can be traced directly back to the Prime Ministers chief advisor, Dominic Cummings.

Cummings set out his vision for the NHS in a February 2019 blog, which although previously reported on has not been fully appreciated for its astonishingly direct implications. While focusing on disease risk, the blog flagged-up Cummings hopes that a new NHS genomics prediction programme would ultimately allow the UK to, not just prevent diseases, but to do so before birth in effect a nod toward the selective breeding techniques at the core of eugenics.

They are using the COVID-19 crisis to erect a corporate superstate powered by mass surveillance and AI. Their grim ambition is to reach into the very DNA of every British citizen.

His vision for what a genomics-focused NHS would look like bears startling resemblance to the core ideas of eugenics the discredited pseudoscience aiming to improve the genetic quality of a human population by selecting for superior groups and excluding those with inferior genes. Its worst manifestations were exemplified by the Nazis.

In the blog, Cummings wrote:

Britain could contribute huge value to the world by leveraging existing assets, including scientific talent and how the NHS is structured, to push the frontiers of a rapidly evolving scientific field genomic prediction. He called for free universal SNP [single-nucleotide polymorphis] genetic sequencing as part of a shift to genuinely preventive medicine, to be rolled-out across the UK. This approach holds the promise of revolutionising healthcare in ways that give Britain some natural advantages over Europe and America.

Later in the post, Cummings allowed himself to speak more directly to what natural advantages could actually entail. He claimed that a combination of AI-driven machine learning with very large genetic sampling could enable the precise prediction of complex traits such as general intelligence and most diseases.

The two scientists Cummings cited as the primary sources for his vision were educational psychologist Robert Plomin and physicist Steven Hsu.

Plomin, described by Cummings as the worlds leading expert on the subject, is a renowned scientist. But he also has a history of association with the eugenics movement, according to Dr David King, founder of Human Genetics Alert and previously a molecular biologist. (Sir David King, the former chief scientific adviser to the UK Government, has also criticised the genome sequencing goldrush).*

When The Bell Curve a book advocating the genetic inferiority of African Americans was published, Plomin was a key signatory to a statement defending the science behind the book, explained Dr David King in a paper for the non-profit watchdog Human Genetics Alert. The statement carefully avoided explicitly endorsing The Bell Curves racist conclusions (aptly summarised by Francis Wheen as black people are more stupid than white people: always have been, always will be. This is why they have less economic and social success), while failing to repudiate them. Plomins fellow co-signatories included several self-proclaimed scientific racists, Philippe Rushton and Richard Lynn. Plomin has also published papers with the American Eugenics Society and spoken at several meetings of the British Eugenics Society (the latter rebranded itself as the Galton Institute in 1989) both of which advocated racial science.

In December 2013, Plomin was called as an expert witness to the House of Commons Education Select Committee, where he called for the Government to focus on the heritability of educational attainment. Twenty-five minutes into the session, Dominic Raab who as Foreign Secretary and First Secretary has stood in for Boris Johnson during his period of absence due to COVID-19 prompted Plomin to focus more specifically on explaining his views about genetics, intelligence and socio-economic status.

Just two months before Plomins parliamentary testimony, a 237-page dossier by Cummings then a top advisor to Education Secretary Michael Gove was leaked to the press. The paper claimed that genetics plays a bigger role in a childs IQ than teaching and called for giving specialist education as per Eton to the top 2% in IQ. Pete Shanks of the Centre for Genetics and Society described Cummings policy proposal as a blatantly eugenic association of genes with intelligence, intelligence with worth, and worth with the right to rule.

The Cummings dossier which cites Plomin extensively further reveals that, according to Cummings, he had invited Plomin into the DfE [Department for Education] to explain the science of IQ and genetics to officials and ministers.

The Education Select Committees report shows that, at the time of Plomins testimony, the Government was resistant to these views. But, the position appears to have changed since then, with figures such as Cummings, Raab and Gove now at the seat of power under Prime Minister Boris Johnson.

Plomin would go on to work with Steven Hsu, who was involved in a major Chinese genome sequencing project based on thousands of samples from very high-IQ people around the world. The goal was to identify genes that can predict intelligence. Hsu went on to launch his own company, Genomic Prediction. In slide presentations about his work from 2012, Hsu approvingly quoted British eugenicist Ronald Fisher, closing his slides with the following quotation: but such a race will inevitably arise in whatever country first sees the inheritance of mental characters elucidated. Hsus slides, wrote David King, include plans for a eugenic breeding scheme using embryo selection to improve the overall IQ of the population.

Yet, on his blog, Cummings confirmed that Hsu has recently attended a conference in the UK where he presented some of these ideas to UK policy-makers. Among the ideas Hsu presented to Cummings colleagues in Government was that the UK could become the world leader in genomic research by combining population-level genotyping with NHS health records. Hsu further claimed that risk prediction for common diseases was already available to guide early interventions that save lives and money.

Hopefully the NHS and Department for Health will play the Gretzky game, take expert advice from the likes of Plomin and Hsu and take this opportunity to make the UK a world leader in one of the most important frontiers in science, enthused Cummings.

Plomins claim that intelligence is determined primarily by genes contradicts a vast body of scientific literature, and is largely overblown. One of the latest studies debunking Cummings hopes was led by the University of Bristol and published in March. Based on a sample size of 3,500 children, the study found that polygenic scores (which combine information from all genetic material across the entire genome) have limited use for accurately predicting individual educational performance or for personalised education.

The study did not dismiss a role for genes outright, noting genetic scores modestly predictededucational achievement. The problem was that these predictions were less accurate than using standard information known to predicteducational outcomes, such as achievement at younger ages, parents educational attainment or family socio-economic position.

Last November, Hsus Genomic Prediction began touting new report cards to its customers. The cards displayed alleged results of genetic tests containing warnings that embryos might have low intelligence, grow up to be short, or have other conditions such as diabetes. But, according to the MIT Technology Review, the company has struggled both to validate its predictions and to interest fertility centres in them. In the month prior to Hsus grand announcement, the first major study to test the empirical viability of screening embryos, led by statistical geneticist Shai Carmi of the Hebrew University of Jerusalem, concluded that the technology is not plausible.

The lack of scientific substantiation has not stopped Cummings from suggesting a more interventionist vision for the NHS, which could be accused of paving the way for a new form of eugenics. In his February 2019 blog, he wrote: We can imagine everybody in the UK being given valuable information about their health for free,truly preventive medicinewhere we target resources at those most at risk, and early (evenin utero) identification of risks. This passage appears to nod to the core eugenics notion of selective breeding using embryo selection. Cummings even went further to endorse the goal of editing genes to fix problems.

In a further telling but slightly more well-known passage, Cummings characterised the genomics programme as a precursor to more realistic views about IQ and social mobility: It ought to go without saying that turning this idea into a political/government success requires focus on A) the NHS, health, science, NOT getting sidetracked into B) arguments about things like IQ and social mobility. Over time, the educated classes will continue to be dragged to more realistic views on (B) but this will be a complex process entangled with many hysterical episodes. (A) requires ruthless focus.

This passage affirms that Cummings approach is deliberately deceptive. The focus on health and the NHS is revealed as a cover for a longer-term vision to usher in more realistic views about things like IQ and social mobility. The passage also lifts the rock on Cummings weakest point that he fears that public attention on these more realistic views could sidetrack the broader strategy before it reaches fruition.

In the words of Dr David King, Cummings deference to Hsu, who openly advocated eugenics breeding programmes, suggests that the Prime Ministers chief advisor clearly favours this strategy for Britain; of course, this is precisely what all the European countries were trying to achieve in the heyday of eugenics to overcome their imperialist competitors by improving the national stock.

This, it seems, is the essence of Cummings ambition to use the NHS genomics prediction programme as a mechanism to provide Britain natural advantages over Europe and America.

And in this context, it is impossible to ignore the implications of Cummings appointment of Andrew Sabisky to a senior role advising Boris Johnson. When Johnsons spokespeople were asked repeatedly whether the Prime Minister would condemn Sabiskys sympathies for racist eugenics, he repeatedly refused. Sabisky later stepped away from the role.

The COVID-19 pandemic has now provided the Government with the opportunity to double down on its goals of extending genome sequencing across the UK population.

While genomic sequencing of the Coronavirus is undoubtedly an important scientific task to map and understand it, the crisis fits neatly into Cummings call for a ruthless focus on the NHS as a vehicle for Britains genetic enhancement.

On 23 March, when the UK finally instituted a lockdown at least three weeks after being informed that hundreds of thousands of people (and potentially up to a million) people were at risk of death from its previous policy of herd immunity, the Government launched a new scientific research consortium coordinated by Cambridge University along with the Wellcome Sanger Institute, the NHS and Public Health England.

The consortium would gather samples from patients confirmed with COVID-19 and send them to genetic sequencing centres across the country to analyse the whole genetic code of the samples. The project was billed breathlessly as an essential step in being able to control the pandemic and prevent further spread.

Unsurprisingly, it has done no such thing. Instead, six weeks later, the UK has ended up with the highest COVID-19 fatality rate in Europe.

As the death toll approaches the same level of British civilian casualties during the Second World War, the Governments strategy has privileged ambiguous, extortionate high technology solutions, pouring hundreds of millions of pounds into powerful private sector players with no transparency or due process. Meanwhile, traditional, proven, public health strategies such as better border controls, or extensive contact tracing and testing by scaling up local capacity, were inexplicably delayed for months.

On 13 March, the Government launched a new partnership between the NHS, Genomics England, the GenOMICC consortium, and US biotech giant Illumina, to conduct a nationwide human whole genome sequencing study targeting COVID-19 patients in 170 intensive care units.

The Governments new genome sequencing partner, Illumina, has previously produced genetic sequencing systems marketed to police agencies in China to facilitate its genetic profiling of the minority Uyghur population in Xinjang the largest system of discriminatory, ethnically-targeted biometric surveillance using DNA ever created.

It is difficult to avoid the conclusion that Dominic Cummings and his fellow ideologues in Government are hell-bent on pursuing a pseudo-scientific vision that has been years in the making.They are using the COVID-19 crisis to erect a corporate superstate powered by mass surveillance and AI. Their grim ambition is to reach into the very DNA of every British citizen.

Dominic Cummings was contacted for this article, but is yet to reply.

*This article was corrected to remove a confusion between Sir David King, the former government chief scientific adviser, and Dr David King, the molecular biologist who isthefounder and Director of Human Genetics Alert.

Go here to see the original:
WHITEHALL ANALYTICA THE AI SUPERSTATE: Part 2 Is COVID-19 Fast-Tracking a Eugenics-Inspired Genomics Programme in the NHS? - Byline Times

Read More...

Class of 2020, we see you : NewsCenter – University of Rochester

Monday, May 18th, 2020

May 12, 2020

As we prepare to confer their degrees this week, were celebrating this years graduates by highlighting members of the class and their accomplishments. Congratulations to the Class of 2020 on everything you have achieved.

MAKING THEIR MARK: Each year, as our students prepare to receive their degrees, we take a moment to gather some members of the graduating class for some parting thoughts on their time here. This year was not a typical year, as everyone has had to get used to remote learning, social distance, and a virtual degree conferral. Despite these challenges, our students have still managed to find perspective on how they have grown in the last four years and what they will take with them in the next phase of their lives.

View this post on Instagram

It's Wednesday and week five of remote classes and online learning, so we're checking in with Rochester students to ask: How are you? Starting online classes has definitely been an adjustment, but it is actually going a lot better than I thought it would. While I miss my favorite campus study spots dearly (a piece of my heart currently resides in the Periodical Reading Room), I've been able to set up a nice spot in my dining room where I can focus pretty well. I appreciate how accommodating and creative my professors have been while adapting to zoom. One of my professors even made a class drinking game, where you bring your favorite health beverage to class and have to drink every time a dog barks, a parent walks in, the wifi goes out, etc. While this is not the senior spring I imagined, I'm so grateful for the continued support of my friends, family, and professors despite the distance between us, whether that is six feet or 600 miles. Rachel Goodman 20 (@rgoody21) is a health, behavior and society and psychology double major from Needham, Massachusetts Swipe for a video message from Rachel and her sweet pupper named Pepper! Hi, everyone! Im Rachel Goodman and Im coming to you from Needham, Massachusetts, with my good boy, Pepper. I hope everyone is staying safe, healthy, and practicing social distancing. I know Ive gone through the big list of important activities. I have watched Tiger King, I cleaned my closet, I re-downloaded the House Party app, but Im starting to run out of some ideas, so if you have any quintessential quarantine activities, please let me know. Just a message to my fellow seniors: Im thinking of you right now. It is a tough time, it is weird. I am feeling it, too. But lets continue to hang in there, check in on each other, and support each other through this. So, in the meantime, please stay safe, stay home, and wash your hands.

A post shared by University of Rochester (@urochester) on Apr 22, 2020 at 10:35am PDT

View this post on Instagram

Class of 2020, we see you. In the weeks leading up to the conferral of their degrees, we meet members of this year's graduating class to hear how they're doing. #UR2020 I'm currently at home with my brother and parents. It's been nice to spend time with my brother, and I have really been enjoying my mom's delicious home cooked South Indian food. I've finally gotten back to reading for pleasure, something that I couldn't do in college. Since leaving the River Campus I've found myself missing unexpected things. I miss the trees on the Academic Quad, and the view of the clocktower from the Douggie steps. Some things I knew I'd miss, like studying with people in Rush Rhees, or those random run-ins with friends around campus. Remote learning has been interesting. The freedom to watch lectures whenever I want has been nice, but I've found that lab classes are difficult to transmit virtually. These past several weeks I've been adjusting to our new reality. I've realized that, moving forward, its up to each person to find the motivation and drive to help others who are affected by the COVID-19 crisis and create the best possible future after this pandemic. I know that the Class of 2020 is up to the task. I've spent four years learning how amazing they are. Vennela Pandaraboyina 20 (@vennela98) is a cell and developmental biology major from Acton, Massachusetts Swipe to see Vennela enjoying one of her favorite remote learning activities.

A post shared by University of Rochester (@urochester) on May 13, 2020 at 12:52pm PDT

View this post on Instagram

Class of 2020, we see you. In the days leading up to the conferral of their degrees, we meet members of this year's graduating class to hear how they're doing. #UR2020 I remember during my college admission process when the University of Rochester asked me what would I contribute to campus to make it Ever Better. I answered with positivity and my annoying knack for optimism. During these trying times, I look to those qualities again to help me and my peers move forward as best as we can. Since being home, I've been able to expand my fleet of plants, try and fail at different cooking masterpieces, and resume my love for art and painting. I know it's not as great as being on campus surrounded by friends, but if Rochester taught us anything during those cold months, it is resiliency, and I know our community will come out stronger and better together. Rita Pecoraro 20 (@rita_pecoraro) is a financial economics major from Cheyenne, Wyoming. She also served as treasurer for the SA Appropriations Committee this year Swipe (and sound on!) to hear the Students Association's Zoom rendition of "YMCA."

A post shared by University of Rochester (@urochester) on May 14, 2020 at 11:52am PDT

THIS IS ONLY THE BEGINNING: For the last four years, Jamal Holtz 20 has called Rochester his home, and from the moment he set foot on campus, he knew he wanted to make an impact here. I always said, when I step onto any community, says Holtz, who was elected to serve as Students Association president in his senior year. I make it a community that I live in, not a community that I just come for four years and leave.

View this post on Instagram

Class of 2020, we see you. In the weeks leading up to the conferral of their degrees, we meet members of this year's graduating class to hear how they're doing. #UR2020 "Looking back on my time at the University of Rochester, Im filled with love and gratitude for the incredible people and memories I have made through being on the womens lacrosse team. This team brought me everything, from teaching me to work hard and to never give up, to bringing me my best friends. There was never a dull moment on this team, and in particular, this year we really would had something special. I cant put into words how incredibly grateful I am to have been able to spend the amount of time that I did with this specific group of women; they have helped me grow not only as an athlete, but as a person and that is a credit to each and every person on this team. The fact that the other seniors and I did not have this sport and team to come back to is heartbreaking. There was so much left to accomplish this season, so many laughs to be had, bus rides to take, blue/gold challenges to win. But I am so grateful for the times we did have, and I would not change a thing about these last three and a half years; I know I will always have a family with these people and I cannot wait to see what they achieve in the years to come. " Maggie McKenna 20 (@mags_mckenna) is a financial economics and mathematics double major from Brighton

A post shared by University of Rochester (@urochester) on May 12, 2020 at 11:12am PDT

View this post on Instagram

Class of 2020, we see you. In the weeks leading up to the conferral of their degrees, we meet members of this year's graduating class to hear how they're doing. #UR2020 Im still living in Rochester, in an off-campus apartment. It has been hard staying motivated, but creating art makes me to feel productive. Im artistically inspired frequently these days. I hate whats going on, but I do my best work when I am sad. I guess its good to know something positive can come from something negativeand have tangible evidence of that idea. I get lonely, but this is the first time Ive ever had a full space to myself and a big fear about graduating and being a real person was how lonely I would be. I used to think I could never lively myself, but I am, and its OK, and even nice at times. I think a big part of why being alone is awful, is FOMO (fear of missing out). But since no one is allowed to see each other, there isnt really anything to miss out on. The hardest part is imagining what life would have been at school. Sitting on the quad in the sun, surrounded by my peers, bopping from one set of friends to the next, just being with each other. Daniela Shapiro 20 (@cds.art) is a philosophy major from West Orange, N.J., and the author of the graphic novel "The Stories of Survivors."

A post shared by University of Rochester (@urochester) on May 11, 2020 at 10:42am PDT

View this post on Instagram

Class of 2020, we see you. In the weeks leading up to the conferral of their degrees, we meet members of this year's graduating class to hear how they're doing. #UR2020 "Since the abrupt end of my final semester on campus, I've been home in Chicago completing the rest of my coursework. The biggest benefit that I've gotten from being home are the nightly meals my mom prepares, and the quick access I have to talk and laugh with my 16-year-old brother. The biggest challenges have been having the self-discipline to focus in class and not open additional tabs on my laptop while my professor speaks. It can be easy to get relaxed with online classes, so I've been taking extra measures to stay on my toes. What's helped me most with focusing has been playing library white noise to drown out any distractions in my home. This has been the best option for me to feel isolated, and ultimately zone out. As a graduating senior, the biggest takeaway has been to take everything at face value, and to always put in what you want to get out. Rochester indubitably prepared me for the real world and has definitely sharpened my work ethic and who I am as a person. Though it's disappointing knowing my senior year won't end the way I hoped, I have a great sense of closure knowing that the relationships I built will last for years to come." Swipe for more words of wisdom from Eugene Eugene Nichols III '20 (@ginonichols) is a communications and social advocacy major from Chicago, Illinois

A post shared by University of Rochester (@urochester) on May 10, 2020 at 11:30am PDT

MOVE-IN DAY: Four year ago, the Class of 2020 arrived at the Universityready to move in, get started, and make their mark. As we celebrate all that theyve accomplished, lets enjoy this look back on their first day as Yellowjackets so we can appreciate how far theyve come.

View this post on Instagram

Class of 2020, we see you. In the weeks leading up to the conferral of their degrees, we meet members of this year's graduating class to hear how they're doing. #UR2020 Remote learning has been a really odd adjustment to make. I've taken over my parents dining room table and pretty much made it my own office. I'm just trying to make it through these last few days and find time to get outside and stay active. Of all my college experiences, those related to being a member of Rochesters track and field program easily represent some of my most meaningful and defining ones. That's what made it so bittersweet when my time as an athlete came to an abrupt end in March. While I fully understand the need for the social distancing measures required to contain COVID-19, it will always sadden me that I missed out on some of those pivotal moments and memories with this truly special team. My first year, I tore my ACL early during the indoor season. At the time, I was afraid that along with losing the rest of the year, I had lost the opportunity to join the team culture. Instead, I was met with so much support from my teammates and coaches and ultimately made some of the friendships I hope to carry with me long after college. Being able to come back and represent the team at championship and national meets and trying to push myself to lead by example has been a tremendous privilege for me. I am so proud to have been a member of this team. Swipe to see how Lonnie continues her track and field workouts from home Lonnie Garrett 20 (@lonnie_garrett) Chemical engineering major from Columbia, Maryland

A post shared by University of Rochester (@urochester) on May 8, 2020 at 12:07pm PDT

View this post on Instagram

Class of 2020, we see you. In the weeks leading up to the conferral of their degrees, we meet members of this year's graduating class to hear how they're doing. #UR2020 Switching to remote learning has been smooth for my computer science classes. My professors are able to deliver lectures over Zoom and we can continue to do our programming assignments. Unfortunately, all of my musical performances have been cancelled, and it can be challenging to stay productive during my practice sessions. I'm grateful that I was able to move a marimba from @eastman.school to my apartment in Rochester, so that I can keep practicing. I probably walk past Eastman once a day, and Im used to seeing 100 other students on the street. So its weird to know that the concert halls and practice rooms are empty. My percussion professor is inviting professional percussionists and composers from all around the world to join us for studio class over Zoom, which is a great learning opportunity. I'm looking forward to the day when I can attend a concert and play for people again! Swipe to hear Olivers stylings on the marimba Oliver Xu 20, 20E (@oxuperc) Dual degree student majoring in percussion and computer science from Livonia, Michigan

A post shared by University of Rochester (@urochester) on May 7, 2020 at 12:28pm PDT

View this post on Instagram

Class of 2020, we see you. In the weeks leading up to the conferral of their degrees, we meet members of this year's graduating class to hear how they're doing. #UR2020 Im at home in Atlanta with my parents and brother, and were all quarantining together. Im comfortable, Im happy, and Im supported by them. Its incredible to see how this pandemic is affecting the world. As an international relations major, Ive always been interested in how certain events are so powerful that they can change how our world works. Most significantly, I think we are being forced to reflect on how much we care about things that we can barely seebe it climate change, the global refugee crisis, or a microscopic virus. Like many, I miss life on campus, whether it be joking with friends in passing, or grabbing lunch with classmates. But, amid these personal struggles and letdowns, I believe it is also important for us to see how we are all part of a bigger whole in this world. By realizing this, perhaps there can be a silver lining to the crisis. Swipe to hear more from Nate Nate Leopold 20 (@nate.leo) International relations and political science double major from Atlanta, and a four-year member of the Yellowjackets mens soccer team

A post shared by University of Rochester (@urochester) on May 6, 2020 at 11:41am PDT

View this post on Instagram

Class of 2020, we see you. In the weeks leading up to the conferral of their degrees, we meet members of this year's graduating class to hear how they're doing. #UR2020 Transitioning to life at home has been quite the adjustment. Im used to spending many hours a day in a silent library and now Im in upstate New York with my two very cute, but not so very quiet puppies! My mom and brother are also here, and we are all healthy, so I feel very blessed. At first, I was able to spend my extra free time hiking, but now most trails are closed. So, Ive resorted to painting scenes from my favorite hikes instead! Heres a painting Im working on right now of Lake Road in Keene Valley. Finding motivation to finish my senior spring semester online has certainly been a challenge. Plus, Im an extreme extrovert, so I miss being around lots of people! My friends and I hold weekly Zooms to stay connected and we usually end up laughing for about three hours each time. Im looking forward to being able to hug all my friends and family again. Stay safe and healthy everyone! Swipe to see Amandas video: I took at an awesome hike in northern Lake George right before many trails got closed. I went with my friend Lauren. We drove separately and hiked 10 feet apart the whole time. Super views!!" Amanda Guido 20 (@amandaguidoo) Molecular genetics major from Lake George, New York

A post shared by University of Rochester (@urochester) on May 5, 2020 at 1:31pm PDT

View this post on Instagram

Class of 2020, we see you. In the weeks leading up to the conferral of their degrees, we meet members of this year's graduating class to hear how they're doing. #UR2020 I got the news that school was over when I was in the middle of a match. I felt extremely overwhelmed and sad. Knowing that was going to be my last match ever, I had to pour my heart out to end things with a win. There were so many events to look forward to this season, and so many more memories to make with my teammates. However, looking back at it, I'm grateful to have been part of this experience and have so many good memories and times with my teammates and best friends. Im staying on the River Campus. Ive walked across campus to get mail, and its pretty sad and quiet. I spend most of my time in my dorm, but I go on runs every evening around Genesee Valley Park. Im also trying a lot of different restaurants around Rochester. Nothing feels real anymore. Every day feels the same. Yifan Shen 20 (@yi.f.shen) Microbiology and business double major from Taichung, Taiwan, and a member of the Yellowjackets' tennis team

A post shared by University of Rochester (@urochester) on May 4, 2020 at 12:03pm PDT

View this post on Instagram

Class of 2020, we see you. In the weeks leading up to the conferral of their degrees, we meet members of this year's graduating class to hear how they're doing. #UR2020 Im staying in the house Ive been renting in Rochester the past year and a half. Before all of this happened, I usually spent only a few hours each day in my room sleeping. If I was awake, Id be on campus going to classes, working at WRUR (as chief engineer), or hanging with friends. Now, Im here all of the time. Remote classes are going well. It really helps that lectures are recorded so I can rewatch something if I need clarification on a topic. And Ive been extremely appreciative of my professors' willingness to conduct class in a way that allows students to ask questions whenever they need. Im also a TA for Engineering in Antiquity, taught by professor Renato Perucchio. I attend Zoom class lectures so I know what students have covered, and Ive expanded my office hours. The events of this semester are shocking. My hope is that our expanded availability will help provide some sense of normalcy and support throughout the rest of this semester. Nathan Nickerson 20 is a mechanical engineering major from Wilmington, Delaware

A post shared by University of Rochester (@urochester) on May 2, 2020 at 12:41pm PDT

Tags: Class of 2020, featured-post-side

Category: Featured

Link:
Class of 2020, we see you : NewsCenter - University of Rochester

Read More...

A floor to herself: UVM international student remains on campus – Burlington Free Press

Friday, May 8th, 2020

Cheyenne Braganza has an entire floor to herself in her dorm building at the University of Vermont.

Her roommate is home in Massachusetts, gone with almost all 10,000-plus UVM undergraduates. The Burlington school told them in mid-March to stay away after spring break rather than return and risk spreading the COVID-19 virus.

Cheyenne Braganza, a sophomore at the University of Vermont, is a native of Kenya. She is among a handful of students remaining on the Burlington campus that stopped hosting in-person classes in mid-March.(Photo: COURTESY)

Braganza is among about 140 international students who, because of COVID-19-related travel complications, remain on campus. She has plenty of peace and quiet in her suite as she and students on-campus and at home continue their studies online in the last few days of final exams.

The solitude is great for doing school work, said the native of Nairobi, Kenya. The sophomore studying molecular genetics has a bathroom to herself, a glorious feeling for a college student. She can play music as loud as she wants.

But its isolating.

It gets lonely because I finished my work for the day and theres not much to do, said Braganza, who turns 21 in June. Her boyfriend, mother, father and brother are seven time zones away in Kenya. She talks with them on the phone during the day, but at night when her school work is done, her loved ones back home have gone to bed and the campus is forest-quiet Braganza feels forsaken.

Cheyenne Braganza of Nairobi, Kenya, says she gets a lot of work done but often feels lonely as one of only a few students remaining on campus at the University of Vermont.(Photo: COURTESY)

She finds comfort in socially-distant interactions with dining-hall workers and students she sees on meal runs. She takes solace in her work, which includes watching videos of scientists performing lab work before calculating data derived from that to write her own reports.

Braganzas career goals are timely. She dreams of doing medical research and running her own lab.

I dont want to treat patients. I want to do more-groundbreaking work, like research on vaccines, she said. Ive always had a passion for research.

More personal stories: How Vermonters are facing life in the coronavirus era

Contact Brent Hallenbeck at (802) 660-1844 or bhallenbeck@freepressmedia.com. Follow Brent on Twitter at http://www.twitter.com/BrentHallenbeck.

All coverage of the coronavirus is being provided for free to our readers. Please consider supporting local journalism by subscribing to the Free Press.

Read or Share this story: https://www.burlingtonfreepress.com/story/life/2020/05/07/kenya-student-few-international-students-uvm/5176580002/

Original post:
A floor to herself: UVM international student remains on campus - Burlington Free Press

Read More...

AMP Publishes Recommendations for Clinical Genotyping Tests to Predict Warfarin Response – Clinical OMICs News

Friday, May 8th, 2020

The Association for Molecular Pathology (AMP) today published consensus recommendations designed to support the design, validation, and interpretation of clinical genotyping tests for the prediction of warfarin response.

The new warfarin genotyping guideline offers a two-tier categorization of alleles that are recommended for inclusion in clinical PGx genotyping assays. Using criteria such as allele frequencies in different populations and ethnicities, the availability of reference materials and other technical considerations, the AMP PGx Working Group recommended a minimum set of alleles and their defining variants that should be included in all clinical warfarin sensitivity genotyping testswhat the guideline defines as Tier 1 PGx variant alleles.

The AMP PGx Working Groupdeveloped the guideline with organizational representation from the College of American Pathologists (CAP) and the Clinical Pharmacogenetics Implementation Consortium (CPIC). The team also defined a Tier 2 list of optional alleles that do not currently meet one or more of the criteria for inclusion in Tier 1. AMP said the recommendations were meant to be a reference guide and not a restrictive listand that it intends to update these recommendations as new data and/or reference materials become available.

Common benign variants in high linkage disequilibrium (LD) with established functional variant(s) are not currently being considered for inclusion as Tier 1 or Tier 2 variant alleles in routine clinical PGx genotyping panels, the Working Group added.

Guideline recommendations have been published in a manuscript, Recommendations for Clinical Warfarin Sensitivity Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists, that was released online ahead of publication inThe Journal of Molecular Diagnostics.

Clinical genotyping assays that help predict warfarin response and optimize a patients dosage requirements have enabled some of the earliest success stories of this precision medicine era, said Victoria M. Pratt, Ph.D., FACMG, Professor and Director of Pharmacogenetics and Molecular Genetics Laboratories, Indiana University School of Medicine, and AMP PGx Working Group Chair. Together, the AMP PGx Working Group defined a standard set of evidence-based recommendations that will help build on these past successes and improve phenotype prediction and test interpretation for all futurewarfarin sensitivity genotyping panels.

Earlier Recommendations

The AMP PGx Working Group previously developed recommendations for clinical CYP2C9 testing that were intended to be applied to CYP2C9-related medications including warfarin. Last year, the Working Group developed recommendations for clinical CYP2C9 testing that were intended to be applied to CYP2C9-related medications including warfarin.

Since then, the Working Group said, the discovery of additional well-characterized genes/alleles contributing to inter-individual variation in warfarin sensitivity created a need for a separate document addressing genes/alleles specifically related to warfarin sensitivity, including the CYP2C9 alleles.

CYP2C9 is a member of the CYP2C subfamily of the cytochrome P450 enzymes, and one of the most abundant and important drug metabolizing enzymes. It acts on approximately 15% of drugs in current clinical use, including ibuprofen and the blood thinner warfarin.As a result, it is currently included in the FDAs Table of Pharmacogenetic Biomarkers in Drug Labeling forseveral FDA-approved drugs.

According to the Working Group, clinicians have been able since 2010 to obtain CYP2C9 and VKORC1 genotypes and use either the FDA prescribing label or PGx dosing algorithms to define warfarin dose requirements for their patients. While experts have contributed to establishing high-quality genotype-based recommendations for warfarin14 and the accessibility of clinical PGx testing continues to increase, the diversity of available testing platforms and variants interrogated have led to inconsistencies in results among labs.

Although the initial CPIC guideline recommendations included variants that are more common among Caucasians and Asians, the updated 2017 guideline incorporated additional variants that are predictors of warfarin dose requirements in patients of African descent, the Working Group noted. In order to implement recommendations from the recent CPIC warfarin guideline, both the availability of self-reported ancestry and interrogation for specific alleles are therefore essential.

The Working Group recognizes that the benefit of genotype-guided dosing for warfarin to reduce under or over dosing episodes in patients from diverse ethnicities will not likely be realized unless testing panels account for appropriate clinical variants that are relevant for the ethnic groups to whom the test is offered, the Group added.

The new guideline on clinical warfarin sensitivity genotyping allele selection is the last in a series of three reports that are intended to facilitate testing and promote standardization for frequently usedpharmacogenetics (PGx)genotyping assays. The latest guideline builds on theearlier recommendations for clinicalCYP2C19andCYP2C9genotyping, according to AMP.

The recommendations should be implemented together with other clinical guidelines such as those issued by the CPIC, which focus primarily on the interpretation of PGx test results and therapeutic recommendations for specific drug-gene pairs.

AMP members are among the earliest adopters of pharmacogenetic testing in clinical settings, said AMP President Karen E. Weck, M.D., who is also a Professor of Pathology and Laboratory Medicine, Professor of Genetics and Director, Molecular Genetics and Pharmacogenomics at University of North Carolina Chapel Hill, and a PGx Working Group Member.This series of guidelines for common clinical PGx genotyping tests is another example of AMPs ongoing commitment to sharing our collective expertise with the broader laboratory community in order to improve professional practice and patient care.

View original post here:
AMP Publishes Recommendations for Clinical Genotyping Tests to Predict Warfarin Response - Clinical OMICs News

Read More...

Page 16«..10..15161718..30..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick